+

WO2018182612A1 - Procédés et dispositifs pouvant être ingérés pour la libération régio-spécifique de cellules souches au site d'une maladie du tractus gastro-intestinal - Google Patents

Procédés et dispositifs pouvant être ingérés pour la libération régio-spécifique de cellules souches au site d'une maladie du tractus gastro-intestinal Download PDF

Info

Publication number
WO2018182612A1
WO2018182612A1 PCT/US2017/024997 US2017024997W WO2018182612A1 WO 2018182612 A1 WO2018182612 A1 WO 2018182612A1 US 2017024997 W US2017024997 W US 2017024997W WO 2018182612 A1 WO2018182612 A1 WO 2018182612A1
Authority
WO
WIPO (PCT)
Prior art keywords
stem cell
disease
location
subject
housing
Prior art date
Application number
PCT/US2017/024997
Other languages
English (en)
Inventor
Mitchell Lawrence Jones
Sharat Singh
Christopher Loren WAHL
Harry Stylli
Original Assignee
Progenity Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenity Inc. filed Critical Progenity Inc.
Priority to PCT/US2017/024997 priority Critical patent/WO2018182612A1/fr
Publication of WO2018182612A1 publication Critical patent/WO2018182612A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6861—Capsules, e.g. for swallowing or implanting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/00064—Constructional details of the endoscope body
    • A61B1/00071—Insertion part of the endoscope body
    • A61B1/0008—Insertion part of the endoscope body characterised by distal tip features
    • A61B1/00097—Sensors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/04—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
    • A61B1/041—Capsule endoscopes for imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
    • A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4216—Diagnosing or evaluating gastrointestinal ulcers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4222—Evaluating particular parts, e.g. particular organs
    • A61B5/4238—Evaluating particular parts, e.g. particular organs stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4222—Evaluating particular parts, e.g. particular organs
    • A61B5/4255—Intestines, colon or appendix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/90—Identification means for patients or instruments, e.g. tags
    • A61B90/98—Identification means for patients or instruments, e.g. tags using electromagnetic means, e.g. transponders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time

Definitions

  • This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with stem cells.
  • the gastrointestinal (GI) tract generally provides a therapeutic medium for an individual's body.
  • therapeutic drugs may need to be dispensed to specified locations within the small intestine or large intestine, which is more effective than oral administration of the therapeutic drugs to cure some medical conditions.
  • therapeutic drugs applied directly within the small intestine would not be contaminated, digested or otherwise compromised in the stomach, and thus allow a higher dose to be delivered at a specific location within the small intestine.
  • dispensing therapeutic drugs directly within the small intestine inside a human body can be difficult, because a device or mechanism (e.g., special formulation) is needed to carry a therapeutically effective dose of drug to a desired location within the small intestine and then automatically deliver the therapeutic drug at the desired location.
  • a device or mechanism also needs to be operated in a safe manner as the device or mechanism needs to enter the human body.
  • a novel treatment paradigm for inflammatory conditions of the gastrointestinal tract is provided herein in one embodiment.
  • the methods and compositions described herein allow for the regio-specific release of therapeutic drugs at or near the site of disease in the gastrointestinal tract.
  • a therapeutic drug By releasing a therapeutic drug locally instead of systemically, the bioavailability of said drug can be increased at the site of injury and/or relative to a decrease in circulation; thereby, resulting in improved overall safety and/or efficacy and fewer side effects.
  • Advantages may include one or more of increased drug engagement at the target, leading to new and more efficacious treatment regimens; and/or lower systemic drug levels, which means reduced toxicity and reduced immunogenicity in the case of biologies.
  • diseases of the gastrointestinal (GI) tract can be treated with live cell therapies that include populations of live bacteria and/or live yeast, stem cells or a medium conditioned by stem cells, or organoids produced from stem cells.
  • live cell therapies that include populations of live bacteria and/or live yeast, stem cells or a medium conditioned by stem cells, or organoids produced from stem cells.
  • a disease of the gastrointestinal tract in a subject comprising:
  • the method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the stem cell.
  • a disease of the large intestine in a subject comprising:
  • a method of treating a disease of the gastrointestinal tract in a subject comprising:
  • the method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the stem cell.
  • a disease of the gastrointestinal tract in a subject comprising:
  • the method comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the stem cell, wherein the pharmaceutical composition is an ingestible device, and the method comprises administering orally to the subject the pharmaceutical composition.
  • a method of treating a disease of the gastrointestinal tract in a subject comprising:
  • releasing a stem cell at a location in the gastrointestinal tract of the subject that is proximate to one or more sites of disease comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the stem cell, wherein the method provides a concentration of the stem cell in the plasma of the subject that is less than 3 ⁇ g/ml.
  • a disease of the large intestine in a subject comprising:
  • the method comprises administering endoscopically to the subject a therapeutically effective amount of the stem cell.
  • a stem cell for use in a method of treating a disease of the gastrointestinal tract in a subject, wherein the method comprises orally administering to the subject an ingestible device loaded with the stem cell, wherein the stem cell is released by the device at a location in the gastrointestinal tract of the subject that is proximate to one or more sites of disease.
  • the present invention provides a composition comprising or consisting of an ingestible device loaded with a therapeutically effective amount of a stem cell, for use in a method of treatment, wherein the method comprises orally administering the composition to the subject, wherein the stem cell is released by the device at a location in the gastrointestinal tract of the subject that is proximate to one or more sites of disease.
  • the present invention provides an ingestible device loaded with a therapeutically effective amount of a stem cell, wherein the device is controllable to release the stem cell at a location in the gastrointestinal tract of the subject that is proximate to one or more sites of disease.
  • the device may be for use in a method of treatment of the human or animal body, for example, any method as described herein.
  • the present invention provides an ingestible device for use in a method of treating a disease of the gastrointestinal tract in a subject, wherein the method comprises orally administering to the subject the ingestible device loaded with a therapeutically effective amount of a stem cell, wherein the stem cell is released by the device at a location in the gastrointestinal tract of the subject that is proximate to one or more sites of disease.
  • An ingestible device as used in the present invention may comprise one or more mechanical and/or electrical mechanisms which actively control release of the stem cell.
  • the ingestible device as used in the present invention may comprise a release mechanism for release of the stem cell (e.g., from a reservoir comprising the stem cell) and an actuator controlling the release mechanism.
  • the ingestible device comprises:
  • an ingestible housing comprising a reservoir having a therapeutically effective amount of the stem cell stored therein;
  • a release mechanism having a closed state which retains the stem cell in the reservoir and an open state which releases the stem cell from the reservoir to the exterior of the device;
  • the ingestible device comprises
  • a housing defined by a first end, a second end substantially opposite from the first end;
  • a reservoir located within the housing and containing the stem cell wherein a first end of the reservoir is attached to the first end of the housing;
  • the exit valve can be considered as the release mechanism having a closed state which retains the stem cell in the reservoir and an open state which releases the stem cell from the reservoir to the exterior of the device, and the mechanism for releasing the stem cell from the reservoir can be considered as the actuator.
  • the one or more disease sites may have been pre-determined (e.g., determined in a step preceding the administration of the composition of the present invention).
  • the disease site(s) may have been determined by imaging the gastrointestinal tract.
  • the disease site(s) may have been pre- determined by endoscopy (e.g., a step of colonoscopy, enteroscopy, or using a capsule endoscope). Determination that the device is proximate to the disease site may therefore comprise a determining that the device is in a location corresponding to this previously- determined disease site.
  • the location of the device in the gut may be detected by tracking the device.
  • the device may comprise a localization mechanism which may be a communication system for transmitting localization data, e.g., by radiofrequency
  • the device may additionally or alternatively comprise a communication system for receiving a signal remotely triggering the actuator and thus causing release of the stem cell.
  • the signal may be sent when it is determined that the device is in the correct location in the gut.
  • the ingestible device may comprise:
  • an ingestible housing comprising a reservoir having a therapeutically effective amount of the stem cell stored therein;
  • a release mechanism having a closed state which retains the stem cell in the reservoir and an open state which releases the stem cell from the reservoir to the exterior of the device;
  • the ingestible device as used in the present invention may comprise an environmental sensor for detecting the location of the device in the gut and/or for detecting the presence of disease in the GI tract.
  • the environment sensor may be an image sensor for obtaining images in vivo.
  • Detecting the presence of disease may comprise, for example, detecting the presence of inflamed tissue, and/or lesions such as ulceration e.g., aphthoid ulcerations, "punched-out ulcers" and/or superficial ulcers of the mucosa, cobblestoning, stenosis, granulomas, crypt abscesses, fissures, e.g., extensive linear fissures, villous atrophy, fibrosis, and/or bleeding.
  • ulceration e.g., aphthoid ulcerations, "punched-out ulcers" and/or superficial ulcers of the mucosa, cobblestoning, stenosis, granulomas, crypt abscesses, fissures, e.g., extensive linear fissures, villous atrophy, fibrosis, and/or bleeding.
  • Detecting the presence of disease may also comprise molecular sensing, such as detecting the amount of an inflammatory cytokine or other marker of inflammation. Such a marker can be measured locally from a biopsy or systemically in the serum.
  • actuation of the release mechanism may be triggered by a processor or controller communicably coupled to the environmental sensor.
  • the device may not require any external signal or control in order to release the drug.
  • the ingestible device may comprise:
  • an ingestible housing comprising a reservoir having a therapeutically effective amount of the stem cell stored therein;
  • a release mechanism having a closed state which retains the stem cell in the reservoir and an open state which releases the stem cell from the reservoir to the exterior of the device;
  • a detector for detecting the location of the device in the gut and/or the presence of diseased tissue
  • a processor or controller which is coupled to the detector and to the actuator and which triggers the actuator to cause the release mechanism to transition from its closed state to its open state when it is determined that the device is in the presence of diseased tissue and/or in a location in the gut that has been predetermined to be proximal to diseased tissue.
  • an ingestible housing comprising a reservoir having a therapeutically effective amount of the stem cell stored therein;
  • a detector coupled to the ingestible housing, the detector configured to detect when the ingestible housing is proximate to a respective disease site of the one of the one or more sites of disease;
  • valve system in fluid communication with the reservoir system; and a controller communicably coupled to the valve system and the detector, the controller configured to cause the valve system to open in response to the detector detecting that the ingestible housing is proximate to the respective disease site so as to release the therapeutically effective amount of the stem cell at the respective disease site.
  • detection that the ingestible housing is proximate to the respective disease site may be based on environmental data indicating the location of the device in the GI tract (and reference to a pre-determined disease site) or on environmental data directly indicating the presence of diseased tissue.
  • the device may further comprise a communication system adapted to transmit the environment data to an external receiver (e.g., outside of the body).
  • This data may be used, for example, for diagnostic purposes.
  • the external receiver may comprise means for displaying the data.
  • this data may be analyzed externally to the device and used to determine when the drug should be released: an external signal may then be sent to the device to trigger release of the drug.
  • the communication system may further be adapted to receive a signal remotely triggering the actuator and thus causing release of the stem cell.
  • the signal may be sent from an external transmitter in response to receipt/analysis and/or assessment of the environmental data, e.g., data indicating that the device has reached the desired location of the gut (where the location of the diseased tissue has been pre-determined) and/or data indicating the presence of diseased tissue.
  • environmental data e.g., data indicating that the device has reached the desired location of the gut (where the location of the diseased tissue has been pre-determined) and/or data indicating the presence of diseased tissue.
  • “External” may be "outside of the body”.
  • the ingestible device may comprise:
  • an ingestible housing comprising a reservoir having a therapeutically effective amount of the stem cell stored therein; a release mechanism having a closed state which retains the stem cell in the reservoir and an open state which releases the stem cell from the reservoir to the exterior of the device; an environmental detector for detecting environmental data indicating the location of the device in the gut and/or the presence of diseased tissue; a communication system for transmitting the environmental data to an external receiver and for receiving a signal from an external transmitter; and an actuator which controls the transition of the release mechanism from the closed to the open state in response to the signal.
  • a stem cell for use in a method of detecting and treating a disease of the gastrointestinal tract in a subject, wherein the method comprises orally administering to the subject an ingestible device loaded with the stem cell, wherein the ingestible device comprises an environmental sensor for determining the presence of diseased tissue in the GI tract, and wherein the stem cell is released by the device at a location in the gastrointestinal tract of the subject that is proximate to one or more sites of disease, as detected by the environmental sensor.
  • the device may be according to any of the embodiments described herein.
  • compositions for use in a method of detecting and treating a disease of the gastrointestinal tract in a subject comprising or consists of an ingestible device loaded with a therapeutically effective amount of a stem cell, wherein the ingestible device comprises an environmental sensor for determining the presence of diseased tissue in the GI tract, and wherein the stem cell is released by the device at a location in the gastrointestinal tract of the subject that is proximate to one or more sites of disease, as detected by the environmental sensor.
  • the device may be according to any of the embodiments described herein.
  • the ingestible device as used in the present invention comprises an environmental sensor for detecting the presence of disease in the GI tract and a communication system as described above
  • the method of treatment may comprise:
  • the presence of disease may be confirmed based on the presence of inflamed tissue and/or lesions associated with any of the disease states referred to herein.
  • the presence of disease may be confirmed based on the presence of inflammation, ulceration e.g., aphthoid ulcerations, "punched-out ulcers" and/or superficial ulcers of the mucosa, cobblestoning, stenosis, granulomas, crypt abscesses, fissures, e.g., extensive linear fissures, villous atrophy, fibrosis, and/or bleeding.
  • the present invention may relate to a system comprising:
  • an ingestible device loaded with a therapeutically effective amount of a stem cell, a release mechanism for release of the stem cell (e.g., from a reservoir comprising the stem cell), an actuator controlling the release mechanism, an environmental sensor for determining the location of the device in the gut and/or for detecting the presence of diseased tissue and a communication system adapted to transmit the environment data and receive a signal triggering the actuator; a receiver and display module for receiving and displaying outside of the body the environment data from the ingestible device;
  • the ingestible device may further comprise an anchoring system for anchoring the device or a portion thereof in a location and an actuator for the anchoring system. This may be triggered in response to a determination that the device is at a location in the gastrointestinal tract of the subject proximate to one or more sites of disease. For instance, this may be detected by the environmental sensor.
  • the triggering may be controlled by a processor in the device, that is, autonomously. A device where the triggering is controlled by a processor in the device is said to be an autonomous device. Alternatively, it may be controlled by a signal sent from outside of the body, as described above.
  • disease of the GI tract may be an inflammatory bowel disease.
  • the disease of the GI tract is ulcerative colitis.
  • the disease of the GI tract is Crohn's disease.
  • gastrointestinal tract diseases that can be treated include, without limitation, inflammatory bowel disease (IBD), Crohn's disease (e.g., active Crohn's disease, refractory Crohn's disease, or fistulizing Crohn's disease), ulcerative colitis, indeterminate colitis, microscopic colitis, infectious colitis, drug or chemical-induced colitis, diverticulitis, and ischemic colitis, gastritis, peptic ulcers, stress ulcers, bleeding ulcers, gastric hyperacidity, dyspepsia, gastroparesis, Zollinger-Ellison syndrome, gastroesophageal reflux disease, short-bowel (anastomosis) syndrome, a hypersecretory state associated with systemic mastocytosis or basophilic leukemia or hyperhistaminemia, Celiac disease (e.g., nontropical Sprue), enteropathy associated with IBD
  • Crohn's disease e.g., active Crohn's disease, refractory Crohn'
  • gastroenteritis colitis associated with radiotherapy or chemotherapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-1, chronic granulomatous disease, food allergies, gastritis, infectious gastritis or enterocolitis (e.g., Helicobacter pylori- infected chronic active gastritis), other forms of gastrointestinal inflammation caused by an infectious agent, pseudomembranous colitis, hemorrhagic colitis, hemolytic-uremic syndrome colitis, diversion colitis, irritable bowel syndrome, irritable colon syndrome, and pouchitis.
  • apparatuses, compositions, and methods disclosed herein are used to treat one gastrointestinal disease.
  • apparatuses, compositions, and methods disclosed herein are used to treat more than one gastrointestinal disease.
  • apparatuses, compositions, and methods disclosed herein are used to treat multiple gastrointestinal diseases that occur in the same area of the gastrointestinal tract (e.g., each disease can occur in the small intestine, large intestine, colon, or any sub-region thereof).
  • apparatuses, compositions, and methods disclosed herein are used to treat multiple gastrointestinal diseases that occur in different areas of the
  • administration e.g., local administration to the gastrointestinal tract
  • stem cell is useful in the treatment of gastrointestinal diseases including, but not limited to, inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, or any of the other gastrointestinal diseases described herein.
  • IBD inflammatory bowel disease
  • ulcerative colitis Crohn's disease
  • any details or embodiments described herein for methods of treatment apply equally to a stem cell, composition or ingestible device for use in said treatment.
  • Any details or embodiments described for a device apply equally to methods of treatment using the device, or to a stem cell or composition for use in a method of treatment involving the device.
  • FIG. 1 provides an exemplary structural diagram illustrating aspects of an ingestible device 100 having a piston to push for drug delivery, according to some embodiments described herein.
  • FIG. 2 provides another exemplary structural diagram illustrating aspects of an ingestible device 100 having a piston to push for drug delivery, according to some embodiments described herein.
  • Gastrointestinal inflammatory disorders are a group of chronic disorders that cause inflammation and/or ulceration in the mucous membrane. These disorders include, for example, inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, indeterminate colitis and infectious colitis), mucositis (e.g., oral mucositis, gastrointestinal mucositis, nasal mucositis and proctitis), necrotizing enterocolitis and esophagitis.
  • inflammatory bowel disease e.g., Crohn's disease, ulcerative colitis, indeterminate colitis and infectious colitis
  • mucositis e.g., oral mucositis, gastrointestinal mucositis, nasal mucositis and proctitis
  • necrotizing enterocolitis and esophagitis necrotizing enterocolitis and esophagitis.
  • IBD Inflammatory Bowel Disease
  • the GI tract can be divided into four main different sections, the oesophagus, stomach, small intestine and large intestine or colon.
  • the small intestine possesses three main subcompartments: the duodenum, j ejunum and ileum.
  • the large intestine consists of six sections: the cecum, ascending colon, transverse colon, ascending colon, sigmoid colon, and the rectum.
  • the small intestine is about 6 m long, its diameter is 2.5 to 3 cm and the transit time through it is typically 3 hours.
  • the duodenum has a C-shape, and is 30 cm long.
  • jejunum and ileum are sections that can freely move.
  • the jejunum is 2.4 m in length and the ileum is 3.6 m in length and their surface areas are 180 m 2 and 280 m 2 respectively.
  • the large intestine is 1.5 m long, its diameter is between 6.3 and 6.5 cm, the transit time though this section is 20 hours and has a reduced surface area of approximately 150 m 2 .
  • the higher surface area of the small intestine enhances its capacity for systemic drug absorption.
  • IBD immunodeficiency virus
  • corticosteroids and immunomodulator therapy e.g., azathioprine, 6 mercaptopurine, and methotrexate administered via traditional routes such as tablet form, oral suspension, or intravenously
  • azathioprine, 6 mercaptopurine, and methotrexate administered via traditional routes such as tablet form, oral suspension, or intravenously
  • steroids monoclonal antibodies targeting tumor necrosis factor alpha (TNF-a), such as infliximab (a chimeric antibody) and adalimumab (a fully human antibody) are currently used in the management of CD.
  • TNF-a tumor necrosis factor alpha
  • infliximab a chimeric antibody
  • adalimumab a fully human antibody
  • Infliximab has also shown efficacy and has been approved for use in UC.
  • approximately 10%-20% of patients with CD are primary nonresponders to anti TNF therapy, and another ⁇ 20%-30% of CD patients lose response over time (Schnitzler et al, Gut 58:492- 500 (2009)).
  • Other adverse events (AEs) associated with anti TNFs include elevated rates of bacterial infection, including tuberculosis, and, more rarely, lymphoma and demyelination (Chang et al, Nat Clin Pract Gastroenterol Hepatology 3:220 (2006); Hoentjen et al, World J. Gastroenterol. 15(17):2067 (2009)).
  • glucocorticoids cyclosporine and azathioprine, which are known to suppress immune response.
  • the GI tract more than any other organ of the body, is continuously exposed to potential antigenic substances such as proteins from food, bacterial byproducts (LPS), etc.
  • GI gastrointestinal
  • UC ulcerative colitis
  • CD Crohn's disease
  • CD Crohn's disease
  • CD Crohn's disease
  • Crohn's disease is the granular, reddish-purple edematous thickening of the bowel wall. With the development of inflammation, these granulomas often lose their circumscribed borders and integrate with the surrounding tissue. Diarrhea and obstruction of the bowel are the predominant clinical features. As with ulcerative colitis, the course of Crohn's disease may be continuous or relapsing, mild or severe, but unlike ulcerative colitis, Crohn's disease is not curable by resection of the involved segment of bowel.
  • Crohn's disease may involve any part of the alimentary tract from the mouth to the anus, although typically it appears in the ileocolic, small-intestinal or colonic- anorectal regions. Histopathologically, the disease manifests by discontinuous
  • the inflammatory infiltrate is mixed, consisting of lymphocytes (both T and B cells), plasma cells, macrophages, and neutrophils. There is a disproportionate increase in IgM- and IgG-secreting plasma cells, macrophages and neutrophils.
  • CDAI Crohn's Disease Activity Index
  • Backward stepwise regression analysis identified eight independent predictors which are the number of liquid or soft stools, severity of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for anti diarrheal drugs, presence of an abdominal mass, hematocrit, and body weight.
  • the final score is a composite of these eight items, adjusted using regression coefficients and standardization to construct an overall CDAI score, ranging from 0 to 600 with higher score indicating greater disease activity.
  • CDAI ⁇ 150 is defined as clinical remission
  • 150 to 219 is defined as mildly active disease
  • 220 to 450 is defined as moderately active disease
  • above 450 is defined as very severe disease (Best WR, et al, Gastroenterology 77:843-6, 1979).
  • Vedolizumab and natalizumab have been approved on the basis of demonstrated clinical remission, i.e. CDAI ⁇ 150.
  • the CDAI has been in use for over 40 years, and has served as the basis for drug approval, it has several limitations as an outcome measure for clinical trials. For example, most of the overall score comes from the patient diary card items (pain, number of liquid bowel movements, and general well-being), which are vaguely defined and not standardized terms (Sandler et al., J. Clin. Epidemiol 41 :451-8, 1988; Thia et al, Inflamm Bowel Dis 17: 105-11, 2011). In addition, measurement of pain is based on a four-point scale rather than an updated seven-point scale. The remaining 5 index items contribute very little to identifying an efficacy signal and may be a source of measurement noise. Furthermore, concerns have been raised about poor criterion validity for the CDAI, a reported lack of correlation
  • the remission score of ⁇ 11 is the CDAI-weighted sum of the average stool frequency and pain scores in a 7-day period, which yielded optimum sensitivity and specificity for identification of CDAI remission (score of ⁇ 150) in a retrospective data analysis of ustekinumab induction treatment for moderate to severe CD in a Phase II clinical study (Gasink C, et al, abstract, ACG Annual Meeting 2014).
  • the PR02 was shown to be sensitive and responsive when used as a continuous outcome measure in a retrospective data analysis of MTX treatment in active CD (Khanna R, et al, Infiamm Bowel Dis 20: 1850-61, 2014) measured by CDAI. Additional outcome measures include the Mayo Clinic Score, the Crohn disease endoscopic index of severity (CDEIS), and the Ulcerative colitis endoscopic index of severity (UCEIS).
  • Additional outcome measures include Clinical remission, Mucosal healing, Histological healing (transmural), MRI or ultrasound for measurement or evaluation of bowel wall thickness, abscesses, fistula and histology.
  • the SES- CD consists of four endoscopic variables (size of ulcers, proportion of surface covered by ulcers, proportion of surface with any other lesions (e.g., inflammation), and presence of narro wings [stenosis]) that are scored in five ileocolonic segments, with each variable, or assessment, rated from 0 to 3.
  • the current treatment goals for CD are to induce and maintain symptom improvement, induce mucosal healing, avoid surgery, and improve quality of life (Lichtenstein GR, et al., Am J Gastroenterol 104:465-83, 2009; Van Assche G, et al., J Crohns Colitis. 4:63-101, 2010).
  • the current therapy of IBD usually involves the administration of antiinflammatory or immunosuppressive agents, such as sulfasalazine, corticosteroids, 6- mercaptopurine/azathioprine, or cyclosporine, all of which are not typically delivered by localized release of a drug at the site or location of disease. More recently, biologies like TNF-alpha inhibitors and IL-12/IL-23 blockers, are used to treat IBD. If anti-inflammatory/immunosuppressive/biologic therapies fail, colectomies are the last line of defense.
  • antiinflammatory or immunosuppressive agents such as sulfasalazine, corticosteroids, 6- mercaptopurine/azathioprine, or cyclosporine, all of which are not typically delivered by localized release of a drug at the site or location of disease.
  • immunosuppressive agents such as sulfasalazine, corticosteroids, 6- mercaptopurine/aza
  • CD Crohn's disease
  • resection removal of a diseased segment of bowel
  • anastomosis reconnection
  • Sections of the small or large intestine may be removed.
  • About 30% of CD patients will need surgery within the first year after diagnosis. In the subsequent years, the rate is about 5% per year.
  • CD is characterized by a high rate of recurrence; about 5% of patients need a second surgery each year after initial surgery.
  • Refining a diagnosis of inflammatory bowel disease involves evaluating the progression status of the diseases using standard classification criteria.
  • the classification systems used in IBD include the Truelove and Witts Index (Truelove S. C. and Witts, L.J. Br Med J. 1955;2: 1041-1048), which classifies colitis as mild, moderate, or severe, as well as Lennard- Jones. (Lennard- Jones JE. Scand J Gastroenterol Suppl 1989; 170:2-6) and the simple clinical colitis activity index (SCCAI). (Walmsley et. al. Gut. 1998;43:29-32) These systems track such variables as daily bowel movements, rectal bleeding, temperature, heart rate, hemoglobin levels, erythrocyte sedimentation rate, weight, hematocrit score, and the level of serum albumin.
  • UC ulcerative colitis
  • CD can appear anywhere in the bowel, with occasional involvement of stomach, esophagus and duodenum, and the lesions are usually described as extensive linear fissures.
  • a definitive diagnosis of ulcerative colitis or Crohn's disease cannot be made and such cases are often referred to as "indeterminate colitis.”
  • Two antibody detection tests are available that can help the diagnosis, each of which assays for antibodies in the blood.
  • the antibodies are "perinuclear anti-neutrophil antibody” (pANCA) and "anti-Saccharomyces cervisiae antibody” (ASCA). Most patients with ulcerative colitis have the pANCA antibody but not the ASCA antibody, while most patients with Crohn's disease have the ASCA antibody but not the pANCA antibody. However, these two tests have shortcomings as some patients have neither antibody and some Crohn's disease patients may have only the pANCA antibody.
  • a third test which measures the presence and accumulation of circulating anti-microbial antibodies - particularly flagellin antibodies, has proven to be useful for detecting susceptibility to Crohn's Disease before disease
  • Ulcerative colitis afflicts the large intestine.
  • the course of the disease may be continuous or relapsing, mild or severe.
  • the earliest lesion is an inflammatory infiltration with abscess formation at the base of the crypts of Lieberkuhn. Coalescence of these distended and ruptured crypts tends to separate the overlying mucosa from its blood supply, leading to ulceration.
  • Symptoms of the disease include cramping, lower abdominal pain, rectal bleeding, and frequent, loose discharges consisting mainly of blood, pus and mucus with scanty fecal particles.
  • a total colectomy may be required for acute, severe or chronic, unremitting ulcerative colitis.
  • the clinical features of UC are highly variable, and the onset may be insidious or abrupt, and may include diarrhea, tenesmus and relapsing rectal bleeding. With fulminant involvement of the entire colon, toxic megacolon, a life-threatening emergency, may occur. Extraintestinal manifestations include arthritis, pyoderma gangrenoum, uveitis, and erythema nodosum.
  • antibody and “immunoglobulin” are used interchangeably in the broadest sense and include monoclonal antibodies (for example, full length or intact monoclonal antibodies), polyclonal antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific, trispecific etc. antibodies so long as they exhibit the desired biological activity) and may also include certain antibody fragments (as described in greater detail herein).
  • An antibody can be human, humanized and/or affinity matured.
  • Antibody fragments comprise only a portion of an intact antibody, where in certain embodiments, the portion retains at least one, and typically most or all, of the functions normally associated with that portion when present in an intact antibody.
  • an antibody fragment comprises an antigen binding site of the intact antibody and thus retains the ability to bind antigen.
  • an antibody fragment for example one that comprises the Fc region, retains at least one of the biological functions normally associated with the Fc region when present in an intact antibody, such as FcRn binding, antibody half-life modulation, ADCC function and complement binding.
  • an antibody fragment is a monovalent antibody that has an in vivo half-life substantially similar to an intact antibody.
  • such an antibody fragment may comprise on antigen binding arm linked to an Fc sequence capable of conferring in vivo stability to the fragment.
  • monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigen. Furthermore, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.
  • the monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U. S. Patent No. 4,816,567; and Morrison et al, Proc. Natl. Acad. Sci. USA 81 :6851 -6855 (1984)).
  • Treatment regimen refers to a combination of dosage, frequency of administration, or duration of treatment, with or without addition of a second medication.
  • Effective treatment regimen refers to a treatment regimen that will offer beneficial response to a patient receiving the treatment.
  • Patient response or “patient responsiveness” can be assessed using any endpoint indicating a benefit to the patient, including, without limitation, (1) inhibition, to some extent, of disease progression, including slowing down and complete arrest; (2) reduction in the number of disease episodes and/or symptoms; (3) reduction in lesional size; (4) inhibition (i.e., reduction, slowing down or complete stopping) of disease cell infiltration into adjacent peripheral organs and/or tissues; (5) inhibition (i.e., reduction, slowing down or complete stopping) of disease spread; (6) decrease of auto-immune response, which may, but does not have to, result in the regression or ablation of the disease lesion; (7) relief, to some extent, of one or more symptoms associated with the disorder; (8) increase in the length of disease-free presentation following treatment; and/or (9) decreased mortality at a given point of time following treatment.
  • responsiveness refers to a measurable response, including complete response (CR) and partial response (PR).
  • complete response or “CR” means the disappearance of all signs of inflammation or remission in response to treatment. This does not necessarily mean the disease has been cured.
  • Partial response refers to a decrease of at least 50% in the severity of inflammation, in response to treatment.
  • a "beneficial response" of a patient to treatment with a therapeutic agent and similar wording refers to the clinical or therapeutic benefit imparted to a patient at risk for or suffering from a gastrointestinal inflammatory disorder from or as a result of the treatment with the agent.
  • Such benefit includes cellular or biological responses, a complete response, a partial response, a stable disease (without progression or relapse), or a response with a later relapse of the patient from or as a result of the treatment with the agent.
  • non-response or “lack of response” or similar wording means an absence of a complete response, a partial response, or a beneficial response to treatment with a therapeutic agent.
  • a patient maintains responsiveness to a treatment" when the patient' s responsiveness does not decrease with time during the course of a treatment.
  • a "symptom" of a disease or disorder is any morbid phenomenon or departure from the normal in structure, function, or sensation, experienced by a subj ect and indicative of disease.
  • the live cell therapy includes populations of live bacteria and/or yeast, optionally in combination with a prebiotic such as a non-digestible carbohydrate, oligosaccharide, or short polysaccharide (e.g., one or more of inulin, oligofructose, galactofructose, a galacto-oligosaccharides, or a xylo-oligosaccharide) and/or an antibiotic.
  • the bacteria or the yeast can be recombinant.
  • the populations of live bacteria and/or yeast can be used to selectively alter beneficial species within the GI tract and/or to reduce detrimental species within the GI tract of the subject.
  • the live cell therapy includes one or more species of bacteria (e.g., two or more, three or more, four or more, five or more, six or more, or seven or more species) that are underrepresented in patients with IBD.
  • the microbiotas of Crohn's disease (CD) and ulcerative colitis (UC) patients have statistically significant differences from those of noninflammatory bowel disease controls, including a reduction in beneficial commensal bacteria in IBD patients relative to non-inflammatory bowel disease patients.
  • members of the phyla Firmicutes e.g., Clostridium clusters XlVa and IV
  • Bacteroidetes e.g., Bacteroides fragilis or Bacteroides vulgatus
  • Actinobacteria e.g., Coriobacteriaceae spp. or Bifidobacterium adolescentis
  • CD and UC patients See, e.g., Frank, et al, Proc Natl Acad Sci USA, 2007, 104: 13780-13785; Forbes, et al, Front Microbiol. , 2016; 7: 1081, and Nagao-Kitamoto and Kamada, Immune Netw. 2017 17(1): 1-12.
  • Clostridium cluster XlVa includes species belonging to, for example, the Clostridium, Ruminococcus , Lachnospira, Roseburia, Eubacterium, Coprococcus, Dorea, and Butyrivibrio genera.
  • Clostridium cluster IV includes species belonging to, for example, the Clostridium, Ruminococcus, Eubacterium and Anaerofllum genera.
  • Faecalibacterium prausnitzii also referred to as Bacteroides praussnitzii
  • Roseburia hominis are less abundant in CD or UC patients. See, e.g., Nagao-Kitamoto and Kamada, 2017, supra.
  • the live cell therapy includes one or more species of bacteria (e.g., two or more, three or more, four or more, five or more, six or more, or seven or more species) that produce a desired product such as a short chain fatty acid (SCFA) (e.g., butyrate, acetate, or propionate) or induce production (e.g., Clostridium butyricum or F prausnitzii) of an anti- inflammatory agent such as interleukin-10 in host cells.
  • SCFA short chain fatty acid
  • an anti- inflammatory agent such as interleukin-10 in host cells. See, e.g., Hayashi, et al , Cell Host Microbe (2013) 13 :711-722.
  • a live cell therapy can be used to reduce detrimental species in the GI tract using, for example, probiotics (i.e., live nonpathogenic organisms) or prebiotics, optionally in combination with an antibiotic.
  • the prebiotics can be a non-digestible carbohydrate, oligosaccharide or short polysaccharide such as inulin, oligofructose, galactofructose, a galacto-oligosaccharide, or a xylo-oligosaccharide, or combinations thereof.
  • probiotics include Lactobacillus spp. such as L.
  • a probiotic includes a combination of two or more bacterial species (e.g., two or more strains of Lactobacilli such as L. acidophilus and . bulgaricus, or L. rhamnosus and . reuteri; or a combination of Lactobacilli and
  • a probiotic can include two or more species of Lactobacilli (e.g., two, three, four, or five species of Lactobacilli), two or more species of Bifidobacteria (e.g., two, three, or four strains of Bifidobacteria), and one or more optional bacteria such as Streptococcus thermophilus .
  • a probiotic can be the VSL#3 formulation and include B. infanti, B lactis, B longum, L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus, and Streptococcus thermophilus. See, e.g., Gionchetti, et al , Gastroenterology, 2000, 119:305-309.
  • the live cell therapy includes one or more species of bacteria (e.g., two or more, three or more, four or more, five or more, six or more, or seven or more species) that are underrepresented in patients with IBD and one or more probiotics (e.g., two or more, three or more, four or more, five or more, six or more, seven or more, or eight or more probiotics).
  • species of bacteria e.g., two or more, three or more, four or more, five or more, six or more, seven or more, or eight or more probiotics.
  • the live cell therapy includes one or more species of bacteria from a healthy donor (e.g., as collected from a stool sample). See, e.g., Vermeire, J Crohns Colitis, 2016, 10(4): 387-394.
  • the bacteria or yeast can be lyophilized, or can be in saline or other pharmaceutical carrier.
  • the ingestible device can deliver from about 1 x 10 6 to about 1 x 10 12 colony forming units (CFU) of bacteria or yeast (e.g., about 1 x 10 6 , 1 x 10 7 , 1 x 10 8 , 1 x 10 9 , 1 x 10 10 , 1 x 10 11 , 1 x 10 12 CFU) to the GI tract of the subject. See e.g., Islam, 2016, supra. Depending on the volume of the cells, multiple doses of the ingestible device may be required to deliver the desired number of cells to the GI tract.
  • CFU colony forming units
  • the live cell therapy can include bacteria or yeast that are genetically modified to produce: one or more products that are anti-inflammatory and/or that can enhance intestinal barrier function, including, for example, interleukin-10, glucagon-like peptide 2 (GLP-2), GLP-1, a short chain fatty acid such as butyrate, propionate, or acetate, IL-2, IL-22, superoxide dismutase (SOD), kynurenine, IL-27, TGF- ⁇ , TGF-2, N- acylphosphatidylethanolamines (NAPEs), elafin (also called peptidase inhibitor 3 or
  • SKALP trefoil factor
  • melatonin PGD2, or kynurenic acid
  • one or more products that can inhibit or neutralize e.g., an antibody or fragment thereof such as a Fab fragment, single- chain antibody, or single domain antibody such as a nanobody, an antisense RNA, a small interfering RNA (siRNA), a short hairpin RNA (shRNA, or a protein)
  • pro-inflammatory molecules such as TNFa, interleukin 6 receptor (IL-6R), IL-13, IL-18, or p40. See, e.g., WO 2016141108; Neurath, Nature, 2014, 7(1): 6-19; Braat, et al , Clin. Gastroenterol. Hepatol, 2006, 4:754-759; and Vandenbroucke, et al. , Mucosal Immunology, 2010, 3:49-56.
  • the live cell therapy includes regulatory T cells (Treg cells).
  • Treg cells regulatory T cells
  • autologous Treg cells e.g., ova-specific T cells
  • PBMCs peripheral blood mononuclear cells
  • ova-specific T cells can be delivered to the GI tract of the subject.
  • Autologous Treg cells can be prepared by isolating peripheral blood mononuclear cells (PBMCs) from the subject's blood and then expanding ova-specific T cells by culturing the PBMCs in the presence of ovalbumin using Drosophila derived artificial antigen presenting cells transfected with specific stimulatory molecules.
  • PBMCs peripheral blood mononuclear cells
  • T cells can be cloned and Ova-Treg clones can be selected based on an ovalbumin- specific IL-10 production.
  • a phase l/2a study in 20 patients showed that a single injection of antigen-specific (ovalbumin) Treg cells was safe in CD and about 40% of the patients show a clinical response after treatment. See, e.g., Neurath, 2014, supra; and Desreumaux, et al. , Gastroenterology, 2012, 143: 1207-1217.
  • the live cell therapy can deliver stem cells to the GI tract of the subject.
  • the delivery of stem cells into the GI tract can offer measurable therapeutic benefit as the stem cells have the ability to differentiate into numerous different cell types, and rejuvenate the surrounding area.
  • a population of cells is delivered within the GI tract that includes at least about 50% stem cells (at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% stem cells).
  • stem cell is used herein to refer to a cell that is capable of differentiating into a two or more different cell types.
  • the term "a stem cell” may refer to one or more stem cells.
  • the stem cells can be hematopoietic stem cells (HSC) capable of differentiating into different types of blood cells, including myeloid and lymphoid lineages of blood cells.
  • HSC can be obtained from bone marrow, cord blood, or peripheral blood, and are commonly used for bone marrow transfusions in combination with chemotherapy to restart the immune system.
  • HSC are CD34 + cells.
  • Cell-surface markers can be identified by any suitable conventional technique, including, for example, positive selection using monoclonal antibodies against cell-surface markers.
  • HSC used in the methods described herein can be, with respect to the subject, autologous or allogenic. HSC have a high immunogenicity. As a result, if autologous HSC are not used, the HLA receptors of the donor and receiver must be matched. HSC can be harvested by mobilizing stem cells from the subject (autologous) or an HLA-matched donor (allogeneic) using granulocyte colony stimulating factor (GCSF) to promote the creation of HSC and their migration into the bloodstream.
  • GCSF granulocyte colony stimulating factor
  • CD34 + cells can be collected from the peripheral blood or BM of the subject or donor, and then the cells can be cryopreserved until infusion or can be placed in a medium such as an alginate hydrogel.
  • stem cells When stored for five days in an alginate- hydrogel in ambient temperature in an air-tight environment, stem cells showed a survival rate of 74-80%.
  • HSC therapy is preceded by chemotherapy, which removes the majority of the T-cells causing the inflammation, followed by administration of the HSC in the ingestible device.
  • the stem cells used in the methods described herein are capable of differentiating into two or more different cell types other than blood cells.
  • the stem cells are capable of differentiating into cells of each of the three embryonic germ layers (i.e., endoderm, ectoderm, and mesoderm).
  • endoderm i.e., endoderm, ectoderm, and mesoderm.
  • mesoderm embryonic germ layers
  • "capable of differentiating” means that a given cell, or its progeny, can proceed to a differentiated phenotype under the appropriate culture conditions. The capacity of the cells to differentiate into at least two cell types can be assayed by methods known in the art.
  • Non-limiting examples of stem cells include embryonic stem cells or adult stem cells such as mesenchymal stem cells (MSC) (also can be referred to as mesenchymal stromal cells) or other multipotent stem cells; endothelial progenitor cells; stem cells from a particular tissue or organ such as intestinal stem cells, adipose stem cells, or testes stem cells; or induced pluripotent stem cells (iPSC).
  • MSC mesenchymal stem cells
  • iPSC induced pluripotent stem cells
  • stem cells from a particular tissue also can be classified as MSC.
  • the stem cells are MSC, which can differentiate into bone, muscle, cartilage, or adipose type cells.
  • MSC can down-regulate inflammation and have a strong immunoregulatory potential.
  • MSC can be obtained from various tissues, including from, for example, bone marrow, placenta, amniotic fluid, Wharton's jelly, amniotic membrane, chorionic villi, umbilical cord, umbilical cord blood, adipose tissue, dental pulp, synovial membrane, or peripheral blood.
  • the MSC can express a variety of different markers, including, for example, one or more of CD105, CD73, CD90, CD13, CD29, CD44, CD10, Stro-1, CD271, SSEA-4, CD 146, CD49f, CD349, GD2, 3G5, SSEA-3, SISD2, Stro-4, MSCA-1, CD56, CD200, PODXl, Soxl l, or TM4SF1 (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more , 9 or more, or 10 or more of such markers), and lack expression of one or more of CD45, CD34, CD14, CD19, and HLA-DR (e.g., lack expression of two or more, three or more, four or more, or five or more such markers).
  • markers including, for example, one or more of CD105, CD73, CD90, CD13, CD29, CD44, CD10, Stro-1, CD271, SSEA-4,
  • MSC can express CD105, CD73, and CD90. In some embodiments, MSC can express CD105, CD73, CD90, CD13, CD29, CD44, and CD10. In some embodiments, MSC can express CD105, CD73, and CD90 and one or more sternness markers such as Stro-1, CD271, SSEA-4, CD146, CD49f, CD349, GD2, 3G5, SSEA-3. SISD2, Stro-4, MSCA-1, CD56, CD200, PODXl, Soxl l, or TM4SF1.
  • sternness markers such as Stro-1, CD271, SSEA-4, CD146, CD49f, CD349, GD2, 3G5, SSEA-3.
  • MSC can express CD105, CD73, CD90, CD 13, CD29, CD44, and CD 10 and one or more sternness markers such as Stro-1, CD271, SSEA-4, CD146, CD49f, CD349, GD2, 3G5, SSEA-3. SISD2, Stro-4, MSCA-1, CD56, CD200, PODXl, Soxl l, or TM4SF1. See, e.g., Lv, et al , Stem Cells, 2014, 32: 1408-1419.
  • the MSC used in the methods described herein can be, with respect to the subject, autologous or allogenic. MSC have a low immunogenicity due to a dearth of HLA receptors on their surface. As a result, allogenic MSC therapy is a far more viable option for patients. Furthermore, MSC are able to downregulate the immune system, which can modulate the inflammation caused in many autoimmune disorders.
  • MSC are commercially available. See, e.g. Prochymal ® from Osiris Therapeutics.
  • MSC can be harvested from bone marrow by ex vivo culture of the adherent cell fraction of bone marrow aspirates.
  • the solid surface to which the MSC adhere can be a plastic material such as a polystyrene plate, optionally coated with poly-D-Lysine, laminin, or other reagent.
  • MSC can be harvested from adipose tissue such as brown or white adipose tissue from subcutaneous, omental/visceral, mammary, gonadal, or other adipose tissue site.
  • adipose tissue such as brown or white adipose tissue from subcutaneous, omental/visceral, mammary, gonadal, or other adipose tissue site.
  • the MSC can be harvested from subcutaneous white adipose tissue such as that isolated from liposuction.
  • the cells can be harvested by mincing the adipose tissue and washing to remove blood. If the adipose tissue is obtained from a liposuction procedure, mincing is not required.
  • the adipose tissue can be incubated with an enzyme such as Type I collagenase, and the stromal vascular fraction (SVF), which contains a variety of cell types including MSC, can be recovered and the MSC selected from the mixed cell population by adherence to a solid surface such as plastic cell culture surface optionally coated as described above.
  • Yield of MSC from adipose tissue is up to 300-fold higher than the yield of MSC from bone marrow. See, e.g., Fellows, et al, Front Genet. 2016, 7:213; LQc mtQur, et al. , J TranslMed. 2016; 14: 145.
  • the MSC can be expanded in cultured, e.g., passaged at least two times, at least three times, at least four times, at least five times, at least six times, at least seven times, at least eight times, at least nine times, or at least ten times.
  • cells can be passaged more than three times to improve the homogeneity of the cell phenotype in the cell population.
  • the cells can be expanded in culture until needed, so long as the homogeneity of the cell phenotype is improved and differential capacity is maintained.
  • the MSC can be cryopreserved until formulated for the ingestible device or can be placed in a medium such as an alginate hydrogel.
  • a medium such as an alginate hydrogel.
  • the viability of MSC cells stored in alginate hydrogels after 50 days at ambient temperature is 80%.
  • the MSC can be coated with antibodies, e.g., anti-vascular cell adhesion molecule-1 (e.g., VCAM-1) antibodies or anti-addressin antibodies, to improve, for example, their ability to target and hone into inflamed lesions in the GI tract. See, e.g., Ko, et ⁇ . , ⁇ Ther. 2010, 18(7): 1365-1372.
  • antibodies e.g., anti-vascular cell adhesion molecule-1 (e.g., VCAM-1) antibodies or anti-addressin antibodies
  • human iPSCs can be generated from adult somatic cells (e.g., fibroblasts, keratinocytes, dental pulp cells, cord blood, or peripheral blood mononuclear cells) or MSC.
  • iPSCs can be generated using retroviral or non-retroviral methods. See, for example, Loh, et ctl, Blood 2009, 113:5476-5479, Okita, et al. , Nat Methods. 2011, 8(5):409- 12, or Okita, et al. , Stem Cells, 2013, 31(3): 458-466.
  • p53 suppression and nontransforming L-Myc can be used to generate human induced pluripotent stem cells (iPSCs) with episomal plasmid vectors encoding OCT3/4, SOX2, KLF4, and LIN28.
  • adult somatic cells can be transduced with retroviruses encoding four pluripotency factors (SOX2, KLF4, c-MYC, and OCT4).
  • Fully reprogrammed iPSCs have similar properties to embryonic stem cells (ESCs).
  • Patient's cells can be used to derive iPSCs, which can then be induced to undergo differentiation into various types of somatic cells, all with the same genetic information as the patient. See, Azizeh-Mitra, et al. , Stem Cells Int. 2016; 6180487.
  • allogenic cells are used to derive iPSCs.
  • the stem cells can be intestinal stem cells (ISC), which can differentiate into intestinal cell subtypes such as globet cells, Paneth cells, and enterocytes. ISC are located at the crypt base within the intestine and can be positive for one or more markers such as Musashi-1 (Msi-1), Ascl2, Bmi-1, Doublecortin and Ca 2+ /calmodulin- dependent kinase-like 1 (DCAMKL1), and Leucin-rich repeat-containing G-protein-coupled receptor 5 (Lgr5). See, e.g., Mohamed, et al, Cytotechnology, 2015 67(2): 177-189.
  • ISC intestinal stem cells
  • ISC or crypts can be used to produce intestinal organoids using a biodegradable scaffold (e.g., poly-gly colic acid), growth factors such as epidermal growth factor (EGF), R- spondin, Jagged- 1 peptide, or Noggin, and extracellular matrix.
  • growth factors such as epidermal growth factor (EGF), R- spondin, Jagged- 1 peptide, or Noggin
  • mesenchymal cells are included in the culture to support the growth.
  • the intestinal organoid can include a central lumen lined by a villus-like epithelium. See, e.g., US20160287670A1 and WO2015183920A2. Pre-clinical studies have demonstrated the intestinal organoid efficacy in differentiating into all GI cell lineages and regrowing parts of the intestine, muscle layer included.
  • the cells can be formulated to include one or more additional compounds such as a growth factor, a plurality of different growth factors, or other compounds that affect cell differentiation and/or proliferation.
  • the ingestible device can deliver from about 1 x 10 6 , 2 x 10 6 , 3 x 10 6 , 4 x 10 6 , 5 x 10 6 , 6 x 10 6 , 7 x 10 6 , 8 x 10 6 , 9 x 10 6 , 10 x 10 6 , or more cells to the GI tract. Depending on the volume of the cells, multiple doses may be required to deliver the desired number of cells.
  • medium conditioned by the stem cells can be delivered to the GI tract of the subject.
  • conditioned medium that includes one or more biomolecules secreted or excreted by the stem cells can be delivered to the GI tract of a subject.
  • the conditioned medium comprises medium in which the stem cells (e.g., MSC or intestinal stem cells) have grown for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 or more days.
  • the conditioned medium comprises medium in which the stem cells (e.g., MSC or intestinal stem cells) have grown to at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% confluence, or up to 100% confluence.
  • the conditioned medium comprises medium in which the stem cells have been differentiated into an adult cell type.
  • Direct visualization of the GI mucosa is useful to detect subtle mucosal alterations, as in inflammatory bowel diseases, as well as any flat or sessile lesions.
  • the GI tract can be imaged using endoscopes, or more recently ingestible devices that are swallowed.
  • MEMS micro-electromechanical systems
  • Endoscopes may comprise a catheter.
  • the catheter may be a spray catheter.
  • a spray catheter may be used to deliver dyes for diagnostic purposes.
  • a spray catheter may be used to deliver a therapeutic agent at the site of disease in the GI tract.
  • the Olypmus PW-205V is a ready-to-use spray catheter that enables efficient spraying for maximal differentiation of tissue structures during endoscopy, but may also be used to deliver drugs diseased tissue.
  • FIG. 1 disclosed in US Provisional Application No. 62/385,553, incorporated by reference herein in its entirety, illustrates an example of an ingestible device for localized delivery of pharmaceutical compositions disclosed herein, in accordance with particular
  • the ingestible device 100 includes a piston or drive element 134 to push for drug delivery, in accordance with particular implementations described herein.
  • the ingestible device 100 may have one or more batteries 131 placed at one end 102a of a housing 101 to provide power for the ingestible device 100.
  • a printed circuit board (PCB) 132 may be placed adjacent to a battery or other power source 131, and a gas generating cell 103 may be mounted on or above the PCB 132.
  • the gas generating cell 103 may be sealed from the bottom chamber (e.g., space including 131 and 132) of the ingestible device 100.
  • a movable piston 134 may be placed adjacent to the gas generating cell 103.
  • gas generation from the gas generating cell 103 may propel a piston 134 to move towards another end 102b of the housing 101 such that the dispensable substance in a reservoir compartment 135 can be pushed out of the housing through a dispensing outlet 107, e.g., the movement is shown at 136, with the piston 134 at a position after dispensing the substance.
  • the dispensing outlet 107 may comprise a plug.
  • the reservoir compartment 135 can store the dispensable substance (e.g., drug substance), or alternatively the reservoir compartment can house a storage reservoir 161 which comprises the dispensable substance.
  • compartment 135 or storage reservoir 161 may have a volume of approximately 600 ⁇ or even more dispensable substance, which may be dispensed in a single bolus, or gradually over a period of time.
  • the battery cells 131 may have a height of 1.65 mm each, and one to three batteries may be used.
  • the height of the piston may be reduced with custom molded part for around 1.5mm to save space.
  • the gas generating cell 103 is integrated with the piston 134, the overall height of the PCB, batteries and gas generating cell in total can be reduced to around 5 mm, thus providing more space for drug storage.
  • a reservoir compartment 135 or a storage reservoir 161 of approximately 600 ⁇ may be used for drug delivery.
  • a reservoir compartment 135 or a storage reservoir 161 of approximately 1300 ⁇ may be used for drug release.
  • at the reservoir 135 or 161 for storing a therapeutically effective amount of the stem cell forms at least a portion of the device housing 101.
  • the therapeutically effective amount of the stem cell can be stored in the reservoir 135 or 161 at a particular pressure, for example, determined to be higher than a pressure inside the GI tract so that once the reservoir 135 or 161 is in fluid communication with the GI tract, the stem cell is automatically released.
  • the reservoir compartment 135 includes a plurality of chambers, and each of the plurality of the chambers stores a different dispensable substance or a different storage reservoir 161.
  • the storage reservoir 161 is a compressible component or has compressible side walls.
  • the compressible component can be composed, at least in part, or coated (e.g., internally) with polyvinyl chloride (PVC), silicone, DEHP (di-2-ethylhexyl phthalate), Tyvek, polyester film, poly olefin, polyethylene, polyurethane, or other materials that inhibit the stem cell from sticking to the reservoir and provide a sterile reservoir environment for the stem cell.
  • PVC polyvinyl chloride
  • silicone silicone
  • DEHP di-2-ethylhexyl phthalate
  • Tyvek polyester film
  • poly olefin polyethylene
  • polyurethane polyurethane
  • the reservoir compartment 135 or storage reservoir 161 can be configured to store stem cell in quantities in the range of 0.01 mL - 2 mL, such as 0.05 mL - 2 mL, such as 0.05 mL - 2 mL, such as 0.6mL - 2 mL.
  • the storage reservoir 161 is attachable to the device housing 101 , for example, in the reservoir compartment. Accordingly, the storage reservoir 135 can be loaded with the stem cell prior to being positioned in and/or coupled to the ingestible device housing 101.
  • the ingestible device housing 101 includes one or more openings configured as a loading port to load the dispensable substance into the reservoir compartment.
  • the ingestible device housing 101 includes one or more openings configured as a vent.
  • the ingestible device housing 101 includes one or more actuation systems (e.g., gas generating cell 103) for pumping the stem cell from the reservoir 135.
  • the actuation system can include a mechanical, electrical,
  • a chemical actuation means may use chemical reaction of mixing one or more reagents to generate a sufficient volume of gas to propel the piston or drive element 134 for drug release.
  • the actuation system can be integrated into the reservoir compartment 135 or can be an auxiliary system acting on or outside of the reservoir compartment 135.
  • the actuation system can include pumping system for pushing/pulling the stem cell out of the reservoir compartment 135 or the actuation system can be configured to cause the reservoir compartment 135 to change structurally so that the volume inside of the reservoir compartment 135 changes, thereby dispensing the stem cell from the reservoir compartment 135.
  • the actuation system can include an energy storage component such as a battery or a capacitor for powering the actuation system.
  • the actuation system can be actuated via gas pressure or a system storing potential energy, such as energy from an elastic reservoir component being expanded during loading of the reservoir and after being positioned in the ingestible device housing 101 being subsequently released from the expanded state when the ingestible device housing is at the location for release within the GI tract.
  • the reservoir compartment 135 can include a membrane portion, whereby the stem cell is dispensed from the reservoir compartment 135 or storage reservoir 161 via osmotic pressure.
  • the storage reservoir 161 is in a form of a bellow that is configured to be compressed via a pressure from the gas generating cell.
  • the stem cell may be loaded into the bellow, which may be compressed by gas generation from the gas generating cell or other actuation means to dispense the dispensable substance through the dispensing outlet 107 and out of the housing 101.
  • the ingestible device includes a capillary plate placed between the gas generating cell and the first end of the housing, and a wax seal between the gas generating cell and the reservoir, wherein the wax seal is configured to melt and the dispensable substance is pushed through the capillary plate by a pressure from the gas generating cell.
  • the shape of the bellow may aid in controlled delivery.
  • the reservoir compartment 135 includes a dispensing outlet, such as a valve or dome slit 162 extending out of an end of the housing 101, in accordance with particular implementations.
  • a dispensing outlet such as a valve or dome slit 162 extending out of an end of the housing 101, in accordance with particular implementations.
  • the reservoir compartment 135 includes one or more valves (e.g. a valve in the dispensing outlet 107) that are configured to move or open to fluidly couple the reservoir compartment 135 to the GI tract.
  • a housing wall of the housing 101 can form a portion of the reservoir compartment 135.
  • the housing walls of the reservoir serve as a gasket.
  • One or more of the one or more valves are positioned in the housing wall of the device housing 101, in accordance with particular implementations.
  • One or more conduits may extend from the reservoir 135 to the one or more valves, in certain implementations.
  • a housing wall of the housing 101 can be formed of a material that is configured to dissolve, for example, in response to contact at the disease site.
  • a housing wall of the housing 101 can be configured to dissolve in response to a chemical reaction or an electrical signal.
  • the one or more valves and/or the signals for causing the housing wall of the housing 101 to dissolve or dissipate can be controlled by one or more processors or controllers positioned on PCB 132 in the device housing 101.
  • the controller is communicably coupled to one or more sensors or detectors configured to determine when the device housing 101 is proximate to a disease site.
  • the sensors or detectors comprise a plurality of electrodes comprising a coating, in certain implementations. Releasing of the stem cell from the reservoir compartment 135 is triggered by an electric signal from the electrodes resulting from the interaction of the coating with the one or more sites of disease site.
  • the one or more sensors can include a chemical sensor, an electrical sensor, an optical sensor, an electromagnetic sensor, a light sensor, and/or a radiofrequency sensor.
  • the device housing 101 can include one or more pumps configured to pump the therapeutically effective amount of the stem cell from the reservoir compartment 135. The pump is communicably coupled to the one or more controllers.
  • the controller is configured to activate the pump in response to detection by the one or more detectors of the disease site and activation of the valves to allow the reservoir 135 to be in fluid communication with the GI tract.
  • the pump can include a fluid actuated pump, an electrical pump, or a mechanical pump.
  • the device housing 101 comprises one or more anchor systems for anchoring the device housing 101 or a portion thereof at a particular location in the GI tract adjacent the disease site.
  • a storage reservoir comprises an anchor system, and the storage reservoir comprising a releasable substance is anchored to the GI tract.
  • the anchor system can be activated by the controller in response to detection by the one or more detectors of the disease site.
  • the anchor system includes legs or spikes configured to extend from the housing wall(s) of the device housing 101.
  • the spikes can be configured to retract and/or can be configured to dissolve over time.
  • An example of an attachable device that becomes fixed to the interior surface of the GI tract is described in PCT Patent Application PCT/US2015/012209, "Gastrointestinal Sensor
  • the reservoir is an anchorable reservoir, which is a reservoir comprising one or more anchor systems for anchoring the reservoir at a particular location in the GI tract adjacent the disease site.
  • the anchor system includes legs or spikes or other securing means such as a piercing element, a gripping element, a magnetic-flux-guiding element, or an adhesive material, configured to extend from the anchorable reservoir of the device housing.
  • the spikes can be configured to retract and/or can be configured to dissolve over time.
  • the anchorable reservoir is suitable for localizing,positioning and/or anchoring.
  • the anchorable reservoir is suitable for localizing, and positioning and/or anchoring by an endoscope.
  • the anchorable reservoir is connected to the endoscope. In some embodiments, the anchorable reservoir is connected to the endoscope in a manner suitable for oral administration. In some embodiments, the anchorable reservoir is connected to the endoscope in a manner suitable for rectal administration. Accordingly, provided herein in some embodiments is an anchorable reservoir is connected to an endoscope wherein the anchorable reservoir comprises a therapeutically effective amount of the stem cell. In some embodiments the endoscope is fitted with a spray catheter.
  • the reservoir is an anchorable reservoir, which is a reservoir comprising one or more anchor systems for anchoring the reservoir at a particular location in the GI tract adjacent the disease site.
  • the anchor system includes legs or spikes configured to extend from the anchorable reservoir of the device housing. The spikes can be configured to retract and/or can be configured to dissolve over time.
  • the anchorable reservoir is suitable for localizing and positioning by an endoscope.
  • the anchorable reservoir is connected to the endoscope.
  • the anchorable reservoir is connected to the endoscope in a manner suitable for oral administration.
  • the anchorable reservoir is connected to the endoscope in a manner suitable for rectal administration. Accordingly, provided herein in some embodiments is an anchorable reservoir is connected to an endoscope wherein the anchorable reservoir comprises a therapeutically effective amount of the stem cell.
  • the endoscope is fitted with a spray catheter.
  • Exemplary embodiments of anchorable reservoirs are as follows.
  • the reservoir is connected to an endoscope.
  • the anchorable reservoir comprises an implant capsule for insertion into a body canal to apply radiation treatment to a selected portion of the body canal.
  • the reservoir includes a body member defining at least one therapeutic treatment material receiving chamber and at least one resilient arm member associated with the body member for removably engaging the body canal when the device is positioned therein.
  • the anchorable reservoir has multiple suction ports and permits multiple folds of tissue to be captured in the suction ports with a single positioning of the device and attached together by a tissue securement mechanism such as a suture, staple or other form of tissue bonding.
  • the suction ports may be arranged in a variety of configurations on the reservoir to best suit the desired resulting tissue orientation.
  • an anchorable reservoir comprises a tract stimulator and/or monitor IMD comprising a housing enclosing electrical stimulation and/or monitoring circuitry and a power source and an elongated flexible member extending from the housing to an active fixation mechanism adapted to be fixed into the GI tract wall is disclosed. After fixation is effected, the elongated flexible member bends into a preformed shape that presses the housing against the mucosa so that forces that would tend to dislodge the fixation mechanism are minimized.
  • the IMD is fitted into an esophageal catheter lumen with the fixation mechanism aimed toward the catheter distal end opening whereby the bend in the flexible member is straightened.
  • the catheter body is inserted through the esophagus into the GI tract cavity to direct the catheter distal end to the site of implantation and fix the fixation mechanism to the GI tract wall.
  • the IMD is ejected from the lumen, and the flexible member assumes its bent configuration and lodges the hermetically sealed housing against the mucosa.
  • a first stimulation/sense electrode is preferably an exposed conductive portion of the housing that is aligned with the bend of the flexible member so that it is pressed against the mucosa.
  • a second stimulation/sense electrode is located at the fixation site.
  • a reservoir for sensing one or more parameters of a patient is anchored to a tissue at a specific site and is released from a device, using a single actuator operated during a single motion.
  • a delivery device may anchor the capsule to the tissue site and release the reservoir from the delivery device during a single motion of the actuator.
  • a device comprising: a reservoir configured to contain a fluid, the reservoir having at least one outlet through which the fluid may exit the reservoir; a fluid contained within the reservoir; a primary material contained within the reservoir and having a controllable effective concentration in the fluid; and at least one electromagnetically responsive control element located in the reservoir or in a wall of the reservoir and adapted for modifying the distribution of the primary material between a first active form carried in the fluid and a second form within the reservoir in response to an incident electromagnetic control signal, the effective concentration being the concentration of the first active form in the fluid, whereby fluid exiting the reservoir carries the primary material in the first active form at the effective concentration.
  • systems and methods are provided for implementing or deploying medical or veterinary devices or reservoirs (a) operable for anchoring at least partly within a digestive tract, (b) small enough to pass through the tract per vias naturales and including a wireless-control component, (c) having one or more protrusions positionable adjacent to a mucous membrane, (d) configured to facilitate redundant modes of anchoring, (e) facilitating a "primary" material supply deployable within a stomach for an extended and/or controllable period, (f) anchored by one or more adaptable extender modules supported by a subject's head or neck, and/or (g) configured to facilitate supporting at least a sensor within a subject's body lumen for up to a day or more.
  • the reservoir is attachable to an ingestible device.
  • the ingestible device comprises a housing and the reservoir is attachable to the housing.
  • the attachable reservoir is also an anchorable reservoir, such as an anchorable reservoir comprising one or more anchor systems for anchoring the reservoir at a particular location in the GI tract as disclosed hereinabove.
  • a stem cell for use in a method of treating a disease of the gastrointestinal tract as disclosed herein, wherein the stem cell is contained in a reservoir suitable for attachment to a device housing, and wherein the method comprises attaching the reservoir to the device housing to form the ingestible device, prior to orally administering the ingestible device to the subject.
  • an attachable reservoir containing a stem cell for use in a method of treating a disease of the gastrointestinal tract, wherein the method comprises attaching the reservoir to a device housing to form an ingestible device and orally administering the ingestible device to a subject, wherein the stem cell is released by device at a location in the gastrointestinal tract of the subject that is proximate to one or more sites of disease.
  • an attachable reservoir containing a stem cell wherein the reservoir is attachable to a device housing to form an ingestible device that is suitable for oral administration to a subject and that is capable of releasing the stem cell at a location in the gastrointestinal tract of the subject that is proximate to one or more sites of disease.
  • the ingestible device includes cameras (e.g., video cameras) that affords inspection of the entire GI tract without discomfort or the need for sedation, thus avoiding many of the potential risks of conventional endoscopy.
  • Video imaging can be used to help determine one or more characteristics of the GI tract, including the location of disease (e.g., presence or location of inflamed tissue and/or lesions associated with inflammatory bowel disease).
  • the ingestible device 101 may comprise a camera for generating video imaging data of the GI tract which can be used to determine, among other things, the location of the device. Examples of video imaging capsules include Medtronic' s PillCamTM, Olympus' Endocapsule®, and IntroMedic's MicroCamTM.
  • Imaging capsules For a review of imaging capsules, see Basar et al. "Ingestible Wireless Capsule Technology: A Review of Development and Future Indication” International Journal of Antennas and Propagation (2012); 1 -14).
  • Other imaging technologies implemented with the device 101 can include thermal imaging cameras, and those that employ ultrasound or Doppler principles to generate different images (see Chinese patent application CN10447361 1 : "Capsule endoscope system having ultrasonic positioning function".
  • Ingestible devices can be equipped with sources for generating reflected light, including light in the Ultraviolet, Visible, Near-infrared and/or Mid-infrared spectrum, and the
  • autofluorescense may be used to characterize GI tissue (e.g., subsurface vessel information), or low-dose radiation (see Check-CapTM) can be used to obtain 3D reconstructed images.
  • GI tissue e.g., subsurface vessel information
  • Check-CapTM low-dose radiation
  • An ingestible device in accordance with particular embodiments of the present invention may comprise a component made of a non-digestible material and containing the stem cell.
  • the material is plastic.
  • the device is single-use.
  • the device is loaded with a drug prior to the time of administration.
  • a medicinal product comprising the device pre-filled with the drug.
  • Various implementations may be used for localization of ingestible devices within the GI tract.
  • certain implementations can include one or more electromagnetic sensor coils, magnetic fields, electromagnetic waves, electric potential values, ultrasound positioning systems, gamma scintigraphy techniques or other radio-tracker technology have been described by others.
  • imaging can be used to localize, for example, using anatomical landmarks or more complex algorithms for 3D reconstruction based on multiple images.
  • Other technologies rely on radio frequency, which relies on sensors placed externally on the body to receive the strength of signals emitted by the capsule.
  • Ingestible devices may also be localized based on reflected light in the medium surrounding the device; pH;
  • Anchoring components may actively actuate and control the capsule position and orientation in different sections of the GI tract. Examples include leg-like or anchor-like mechanisms that can be deployed by an ingestible device to resist peristaltic forces in narrowed sections of the GI tract, such as the intestine, and anchor the device to a location. Other systems employ magnetic shields of different shapes that can interact with external magnetic fields to move the device. These mechanisms may be particularly useful in areas outside of the small intestine, like the cecum and large intestine.
  • An anchoring mechanism may be a mechanical mechanism.
  • a device may be a capsule comprising a plurality of legs configured to steer the capsule.
  • the number of legs in the capsule may be, for example, two, four, six, eight, ten or twelve.
  • the aperture between the legs of the device may be up to about 35 mm; about 30 to about 35 mm; about 35 to about 75 mm; or about 70 to about 75 mm.
  • the contact area of each leg may be varied to reduce impact on the tissue.
  • One or more motors in the capsule may each actuate a set of legs independently from the other.
  • the motors may be battery-powered motors.
  • An anchoring mechanism may be a non-mechanical mechanism.
  • a device may be a capsule comprising a permanent magnet located inside the capsule. The capsule may be anchored at the desired location of the GI tract by an external magnetic field.
  • An anchoring mechanism may comprise a non-mechanical mechanism and a mechanical mechanism.
  • a device may be a capsule comprising one or more legs, one or more of which are coated with an adhesive material. Locomotion components
  • Ingestible devices can be active or passive, depending on whether they have controlled or non-controlled locomotion. Passive (non-controlled) locomotion is more commonly used among ingestible devices given the challenges of implementing a locomotion module. Active (controlled) locomotion is more common in endoscopic ingestible capsules.
  • a capsule may comprise a miniaturized locomotion system (internal locomotion).
  • Internal locomotion mechanisms may employ independent miniaturized propellers actuated by DC brushed motors, or the use of water jets.
  • a mechanism may comprise flagellar or flap-based swimming mechanisms.
  • a mechanism may comprise cyclic compression/extension shape-memory alloy (SMA) spring actuators and anchoring systems based on directional micro-needles.
  • SMA shape-memory alloy
  • a mechanism may comprise six SMA actuated units, each provided with two SMA actuators for enabling bidirectional motion.
  • a mechanism may comprise a motor adapted to electrically stimulating the GI muscles to generate a temporary restriction in the bowel.
  • a capsule may comprise a magnet and motion of the capsule is caused by an external magnetic field.
  • a locomotion system may comprise an ingestible capsule and an external magnetic field source.
  • the system may comprise an ingestible capsule and magnetic guidance equipment such as, for example, magnetic resonance imaging and computer tomography, coupled to a dedicated control interface.
  • drug release mechanisms may also be triggered by an external condition, such as temperature, pH, movement, acoustics, or combinations thereof.
  • Ingestible devices may comprise a mechanism adapted to permit the collection of tissue samples. In some examples, this is achieved using electro-mechanical solutions to collect and store the sample inside an ingestible device.
  • a biopsy mechanism may include a rotational tissue cutting razor fixed to a torsional spring or the use of microgrippers to fold and collect small biopsies.
  • Over-the-scope clips (OTSC®) may be used to perform endoscopic surgery and/or biopsy.
  • the method may comprise releasing a stem cell and collecting a sample inside the device.
  • the method may comprise releasing a stem cell and collecting a sample inside the device in a single procedure.
  • An ingestible device may be equipped with a communication system adapted to transmit and/or receive data, including imaging and/or localization data.
  • a communication system adapted to transmit and/or receive data, including imaging and/or localization data.
  • radiofrequency transmission Ingestible devices using radiofrequency communication are attractive because of their efficient transmission through the layers of the skin. This is especially true for low frequency transmission (UHF-433 ISM and lower, including the Medical Device Radio Communication Service band (MDRS) band 402-406MHz).
  • acoustics are used for communications, including the transmission of data.
  • an ingestible capsule may be able to transmit information by applying one or more base voltages to an electromechanical transducer or piezoelectric (e.g., PZT, PVDF, etc.) device to cause the piezoelectric device to ring at particular frequencies, resulting in an acoustic transmission.
  • a multi-sensor array for receiving the acoustic transmission may include a plurality of acoustic transducers that receive the acoustic transmission from a movable device such as an ingestible capsule as described in US Patent Application No. 11/851214 filed September 6, 2007, incorporated by reference herein in its entirety.
  • a communication system may employ human body communication technology.
  • Human body communication technology uses the human body as a conductive medium, which generally requires a large number of sensor electrodes on the skin.
  • a communication system may integrate a data storage system.
  • the device may comprise environmental sensors to measure pH, temperature, transit times, or combinations thereof.
  • environmental sensors include, but are not limited to a capacitance sensor, an impedance sensor, a heart rate sensor, acoustic sensor such as a microphone or hydrophone, image sensor, and/or a movement sensor.
  • the ingestible device comprises a plurality of different environmental sensors for generating different kinds of environmental data.
  • the patient is given a patency capsule a few days before swallowing an ingestible device.
  • Any dissolvable non-endoscopic capsule may be used to determine the patency of the GI tract.
  • the patency capsule is usually the same size as the ingestible device and can be made of cellophane.
  • the patency capsule contains a mixture of barium and lactose, which allows visualization by x-ray.
  • the patency capsule may also include a radiotag or other label, which allows for it to be detected by radio- scanner externally.
  • the patency capsule may comprise wax plugs, which allow for intestinal fluid to enter and dissolve the content, thereby dividing the capsule into small particles.
  • the methods herein comprise (a) identifying a subj ect having a disease of the gastrointestinal tract and (b) evaluating the subject for suitability to treatment.
  • the methods herein comprise evaluating for suitability to treatment a subject identified as having a disease of the gastrointestinal tract.
  • evaluating the subject for suitability to treatment comprises determining the patency of the subject's GI tract.
  • an ingestible device comprises a tissue anchoring mechanism for anchoring the ingestible device to a subj ect's tissue.
  • a tissue anchoring mechanism for anchoring the ingestible device to a subj ect's tissue.
  • an ingestible device could be administered to a subject and once it reaches the desired location, the tissue attachment mechanism can be activated or deployed such that the ingestible device, or a portion thereof, is anchored to the desired location.
  • the tissue anchoring mechanism is reversible such that after initial anchoring, the tissue attachment device is retracted, dissolved, detached, inactivated or otherwise rendered incapable of anchoring the ingestible device to the subject's tissue.
  • the attachment mechanism is placed endoscopically.
  • a tissue anchoring mechanism comprises an osmotically-driven sucker.
  • the osmotically-driven sucker comprises a first valve on the near side of the osmotically-driven sucker (e.g., near the subject's tissue) and a second oneway valve that is opened by osmotic pressure on the far side of the osmotically-driven sucker, and an internal osmotic pump system comprising salt crystals and semi-permeable membranes positioned between the two valves.
  • osmotic pressure is used to adhere the ingestible device to the subject's tissue without generating a vacuum within the ingestible capsule.
  • the osmotic system After the osmotic system is activated by opening the first valve, fluid is drawn in through the sucker and expelled through the second burst valve. Fluid continues to flow until all the salt contained in the sucker is dissolved or until tissue is drawn into the sucker. As liminal fluid is drawn through the osmotic pump system, solutes build up between the tissue and the first valve, reducing osmotic pressure. In some embodiments, the solute buildup stalls the pump before the tissue contacts the valve, preventing tissue damage.
  • a burst valve is used on the far side of the osmotically-driven sucker rather than a one-way valve, such that luminal fluid eventually clears the saline chamber and the osmotic flow reverses, actively pushing the subject's tissue out of the sucker.
  • the ingestible device may be anchored to the interior surface of tissues forming the GI tract of a subject.
  • the ingestible device comprises a connector for anchoring the device to the interior surface of the GI tract.
  • the connector may be operable to ingestible device to the interior surface of the GI tract using an adhesive, negative pressure and/or fastener.
  • a device comprises a tract stimulator and/or monitor IMD comprising a housing enclosing electrical stimulation and/or monitoring circuitry and a power source and an elongated flexible member extending from the housing to an active fixation mechanism adapted to be fixed into the GI tract wall is disclosed. After fixation is effected, the elongated flexible member bends into a preformed shape that presses the housing against the mucosa so that forces that would tend to dislodge the fixation mechanism are minimized.
  • the IMD is fitted into an esophageal catheter lumen with the fixation mechanism aimed toward the catheter distal end opening whereby the bend in the flexible member is straightened.
  • the catheter body is inserted through the esophagus into the GI tract cavity to direct the catheter distal end to the site of implantation and fix the fixation mechanism to the GI tract wall.
  • the IMD is ejected from the lumen, and the flexible member assumes its bent configuration and lodges the hermetically sealed housing against the mucosa.
  • a first stimulation/sense electrode is preferably an exposed conductive portion of the housing that is aligned with the bend of the flexible member so that it is pressed against the mucosa.
  • a second stimulation/sense electrode is located at the fixation site.
  • a device in some embodiments includes a fixation mechanism to anchor the device to tissue within a body lumen, and a mechanism to permit selective de-anchoring of the device from the tissue anchoring site without the need for endoscopic or surgical intervention.
  • An electromagnetic device may be provided to mechanically actuate the de-anchoring mechanism.
  • a fuse link may be electrically blown to de-anchor the device.
  • a rapidly degradable bonding agent may be exposed to a degradation agent to de-anchor the device from a bonding surface within the body lumen.
  • a device is as disclosed in patent publication WO20151 12575 Al , incorporated by reference herein in its entirety.
  • the patent publication is directed to a gastrointestinal sensor implantation system.
  • an orally-administrable capsule comprises a tissue capture device or reservoir removably coupled to the orally- administrable capsule, where the tissue capture device including a plurality of fasteners for anchoring the tissue capture device to gastrointestinal tissue within a body
  • the ingestible device contains an electric energy emitting means, a radio signal transmitting means, a medicament storage means and a remote actuatable medicament releasing means.
  • the capsule signals a remote receiver as it progresses through the alimentary tract in a previously mapped route and upon reaching a specified site is remotely triggered to release a dosage of medicament. Accordingly, in some embodiments, releasing the stem cell is triggered by a remote electromagnetic signal.
  • the ingestible device includes a housing introducible into a body cavity and of a material insoluble in the body cavity fluids, but formed with an opening covered by a material which is soluble in body cavity fluids.
  • a diaphragm divides the interior of the housing into a medication chamber including the opening, and a control chamber.
  • An electrolytic cell in the control chamber generates a gas when electrical current is passed therethrough to deliver medication from the medication chamber through the opening into the body cavity at a rate controlled by the electrical current.
  • releasing the stem cell is triggered by generation in the composition of a gas in an amount sufficient to expel the stem cell.
  • the ingestible device includes an oral drug delivery device having a housing with walls of water permeable material and having at least two chambers separated by a displaceable membrane.
  • the first chamber receives drug and has an orifice through which the drug is expelled under pressure.
  • the second chamber contains at least one of two spaced apart electrodes forming part of an electric circuit which is closed by the ingress of an aqueous ionic solution into the second chamber. When current flows through the circuit, gas is generated and acts on the displaceable membrane to compress the first chamber and expel the active ingredient through the orifice for progressive delivery to the gastrointestinal tract.
  • the ingestible device includes an ingestible device for delivering a substance to a chosen location in the GI tract of a mammal includes a receiver of
  • the receiver includes a coiled wire that couples the energy field, the wire having an air or ferrite core.
  • the invention includes an apparatus for generating the electromagnetic radiation, the apparatus including one or more pairs of field coils supported in a housing.
  • the device optionally includes a latch defined by a heating resistor and a fusible restraint.
  • the device may also include a flexible member that may serve one or both the functions of activating a transmitter circuit to indicate dispensing of the substance; and restraining of a piston used for expelling the substance.
  • the ingestible device includes an ingestible device for delivering a substance to a chosen location in the GI tract of a mammal includes a receiver of
  • the receiver includes a coiled wire that couples the energy field, the wire having an air or ferrite core.
  • the invention includes an apparatus for generating the electromagnetic radiation, the apparatus including one or more pairs of field coils supported in a housing.
  • the device optionally includes a latch defined by a heating resistor and a fusible restraint.
  • the device may also include a flexible member that may serve one or both the functions of activating a transmitter circuit to indicate dispensing of the substance; and restraining of a piston used for expelling the substance.
  • the ingestible device is a device a swallowable capsule.
  • a sensing module is disposed in the capsule.
  • a bioactive substance dispenser is disposed in the capsule.
  • a memory and logic component is disposed in the capsule and in communication with the sensing module and the dispenser.
  • localized administration is implemented via an electronic probe which is introduced into the intestinal tract of a living organism and which operates autonomously therein, adapted to deliver one or more therapy agents.
  • the method includes loading the probe with one or more therapy agents, and selectively releasing the agents from the probe at a desired location of the intestinal tract in order to provide increased efficacy over traditional oral ingestion or intravenous introduction of the agent(s).
  • the ingestible device includes electronic control means for dispensing the drug substantially to the diseased tissue sites of the GI tract, according to a predetermined drug release profile obtained prior to administration from the specific mammal. Accordingly, in some embodiments, releasing the stem cell is triggered by an electromagnetic signal generated within the device. The releasing may occur according to a pre-determined drug release profile.
  • the ingestible device can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element.
  • the release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism.
  • Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
  • the ingestible device includes an electronic pill comprising at least one reservoir with a solid powder or granulate medicament or formulation , a discharge opening and an actuator responsive to control circuitry for displacing medicine from the reservoir to the discharge opening.
  • the medicament or formulation comprises a dispersion of one or more active ingredients ⁇ e.g., solids in powder or granulate form-in an inert carrier matrix.
  • the active ingredients are dispersed using intestinal moisture absorbed into the pill via a semi-permeable wall section.
  • the ingestible device includes a sensor comprising a plurality of electrodes having a miniature size and a lower power consumption and a coating exterior to the electrodes, wherein the coating interacts with a target condition thereby producing a change in an electrical property of the electrodes, wherein the change is transduced into an electrical signal by the electrodes.
  • releasing the stem cell is triggered by an electric signal by the electrodes resulting from the interaction of the coating with the one or more sites of disease.
  • a system for medication delivery comprising such sensor and a pill.
  • the ingestible device includes an electronic pill comprising a plurality of reservoirs, each of the reservoirs comprising a discharge opening covered by a removable cover.
  • the pill comprises at least one actuator responsive to control circuitry for removing the cover from the discharge opening.
  • the actuator can for example be a spring loaded piston breaking a foil cover when dispensing the medicament.
  • the cover can be a rotatable disk or cylinder with an opening which can be brought in line with the discharge opening of a reservoir under the action of the actuator.
  • the ingestible device includes an electronically and remotely controlled pill or medicament delivery system.
  • the pill includes a housing; a reservoir for storing a medicament; an electronically controlled release valve or hatch for dispensing one or more medicaments stored in the reservoir while traversing the gastrointestinal tract; control and timing circuitry for opening and closing the valve; and a battery.
  • the control and timing circuitry opens and closes the valve throughout a dispensing time period in accordance with a preset dispensing timing pattern which is programmed within the control and timing circuitry.
  • RF communication circuitry receives control signals for remotely overriding the preset dispensing timing pattern, reprogramming the control and timing circuitry or terminating the dispensing of the medicament within the body.
  • the ingestible device includes an electronic capsule which has a discrete drive element comprising: a housing, electronics for making the electronic capsule operable, a pumping mechanism for dosing and displacing a substance, a power source for powering the electronic capsule and enabling the electronics and the pumping mechanism to operate, and a locking mechanism; and a discrete payload element comprising: a housing, a reservoir for storing the substance, one or more openings in the housing for releasing the substance from the reservoir and a locking mechanism for engaging the drive element locking mechanism. Engagement of the drive element locking mechanism with the payload element locking mechanism secures the drive element to the payload element, thereby making the electronic capsule operable and specific.
  • a discrete drive element comprising: a housing, electronics for making the electronic capsule operable, a pumping mechanism for dosing and displacing a substance, a power source for powering the electronic capsule and enabling the electronics and the pumping mechanism to operate, and a locking mechanism
  • a discrete payload element comprising: a
  • the ingestible device may be a mucoadhesive device configured for release of an active agent.
  • the ingestible device includes an apparatus that includes an ingestible medical treatment device, which is configured to initially assume a contracted state having a volume of less than 4 cm 3 .
  • the device includes a gastric anchor, which initially assumes a contracted size, and which is configured to, upon coming in contact with a liquid, expand sufficiently to prevent passage of the anchor through a round opening having a diameter of between 1 cm and 3 cm.
  • the device also includes a duodenal unit, which is configured to pass through the opening, and which is coupled to the gastric anchor such that the duodenal unit is held between 1 cm and 20 cm from the gastric anchor.
  • the ingestible device includes a medical robotic system and method of operating such comprises taking intraoperative external image data of a patient anatomy, and using that image data to generate a modeling adjustment for a control system of the medical robotic system (e.g., updating anatomic model and/or refining instrument registration), and/or adjust a procedure control aspect (e.g., regulating substance or therapy delivery, improving targeting, and/or tracking performance).
  • a medical robotic system and method of operating such comprises taking intraoperative external image data of a patient anatomy, and using that image data to generate a modeling adjustment for a control system of the medical robotic system (e.g., updating anatomic model and/or refining instrument registration), and/or adjust a procedure control aspect (e.g., regulating substance or therapy delivery, improving targeting, and/or tracking performance).
  • the ingestible device may also include one or more environmental sensors.
  • Environmental sensor may be used to generate environmental data for the environment external to device in the gastrointestinal (GI) tract of the subject.
  • environmental data is generated at or near the location within the GI tract of the subject where a drug is delivered.
  • Examples of environmental sensor include, but are not limited to a capacitance sensor, a temperature sensor, an impedance sensor, a pH sensor, a heart rate sensor, acoustic sensor, image sensor (e.g., a hydrophone), and/or a movement sensor (e.g., an accelerometer).
  • the ingestible device comprises a plurality of different environmental sensors for generating different kinds of environmental data.
  • the image sensor is a video camera suitable for obtaining images in vivo of the tissues forming the GI tract of the subject.
  • the environmental data is used to help determine one or more characteristics of the GI tract, including the location of disease (e.g., presence or location of inflamed tissue and/or lesions associated with inflammatory bowel disease).
  • the ingestible device may comprise a camera for generating video imaging data of the GI tract which can be used to determine, among other things, the location of the device.
  • the ingestible device described herein may be localized using a gamma scintigraphy technique or other radio-tracker technology as employed by Phaeton Research's EnterionTM capsule (See Teng, Renli, and Juan Maya. "Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers. " Journal of Drug Assessment 3.1 (2014): 43-50), or monitoring the magnetic field strength of permanent magnet in the ingestible device (see T. D. Than, et al, "A review of localization systems for robotic endoscopic capsules," IEEE Trans. Biomed. Eng., vol. 59, no. 9, pp. 2387-2399, Sep. 2012).
  • drug delivery is triggered when it encounters the site of disease in the GI tract.
  • the one or more environmental sensors measure pH, temperature, transit times, or combinations thereof.
  • releasing the stem cell is dependent on the pH at or in the vicinity of the location.
  • the pH in the jejunum is from 6.1 to 7.2, such as 6.6.
  • the pH in the mid small bowel is from 7.0 to 7.8, such as 7.4.
  • the pH in the ileum is from 7.0 to 8.0, such as 7.5.
  • the pH in the right colon is from 5.7 to 7.0, such as 6.4.
  • the pH in the mid colon is from 5.7 to 7.4, such as 6.6.
  • the pH in the left colon is from 6.3 to 7.7, such as 7.0.
  • the gastric pH in fasting subjects is from about
  • the gastric pH in fed subjects is from 3.9 to 7.0, such as from 3.9 to 6.7, such as from 3.9 to 6.4, such as from 3.9 to 5.8, such as from 3.9 to 5.5, such as from 3.9 to 5.4, such as from 4.3 to 7.0, such as from 4.3 to 6.7, such as from 4.3 to 6.4, such as from 4.3 to 5.8, such as from 4.3 to 5.5, such as from 4.3 to 5.4.
  • the pH in the duodenum is from 5.8 to 6.8, such as from 6.0 to 6.8, such as from 6.1 to 6.8, such as from
  • 6.2 to 6.8, such as from 5.8 to 6.7, such as from 6.0 to 6.7, such as from 6.1 to 6.7, such as from 6.2 to 6.7, such as from 5.8 to 6.6, such as from 6.0 to 6.6, such as from 6.1 to 6.6, such as from 6.2 to 6.6, such as from 5.8 to 6.5, such as from 6.0 to 6.5, such as from 6.1 to 6.5, such as from 6.2 to 6.5.
  • releasing the stem cell is not dependent on the pH at or in the vicinity of the location. In some embodiments, releasing the stem cell is triggered by degradation of a release component located in the capsule. In some embodiments, the stem cell is not triggered by degradation of a release component located in the capsule. In some
  • releasing the stem cell is not dependent on enzymatic activity at or in the vicinity of the location. In some embodiments, releasing the stem cell is not dependent on bacterial activity at or in the vicinity of the location.
  • the pharmaceutical composition is an ingestible device, comprising: a housing defined by a first end, a second end substantially opposite from the first end, and a wall extending longitudinally from the first end to the second end;
  • a reservoir located within the housing and containing the stem cell
  • the ingestible device further comprises:
  • a gas generating cell located within the housing and adjacent to the electronic component
  • the electronic component is configured to activate the gas generating cell to generate gas.
  • the ingestible device further comprises:
  • safety device is configured to relieve an internal pressure within the housing when the internal pressure exceeds a threshold level.
  • the pharmaceutical composition is an ingestible device, comprising: a housing defined by a first end, a second end substantially opposite from the first end, and a wall extending longitudinally from the first end to the second end;
  • a gas generating cell located within the housing and adjacent to the electronic component
  • the electronic component is configured to activate the gas generating cell to generate gas
  • the reservoir stores a dispensable substance and a first end of the reservoir is attached to the first end of the housing;
  • exit valve is configured to allow the dispensable substance to be released out of the first end of the housing from the reservoir
  • safety device is configured to relieve an internal pressure within the housing when the internal pressure exceeds a threshold level.
  • the pharmaceutical composition is an ingestible device, comprising: a housing defined by a first end, a second end substantially opposite from the first end, and a wall extending longitudinally from the first end to the second end; an electronic component located within the housing,
  • a gas generating cell located within the housing and adjacent to the electronic component
  • the electronic component is configured to activate the gas generating cell to generate gas
  • the reservoir stores a dispensable substance and a first end of the reservoir is attached to the first end of the housing;
  • jet injection device configured to inject the dispensable substance out of the housing from the reservoir
  • safety device is configured to relieve an internal pressure within the housing.
  • the pharmaceutical composition is an ingestible device, comprising: a housing defined by a first end, a second end substantially opposite from the first end, and a wall extending longitudinally from the first end to the second end;
  • an optical sensing unit located on a side of the housing
  • optical sensing unit is configured to detect a reflectance from an environment external to the housing
  • a gas generating cell located within the housing and adjacent to the electronic component
  • the electronic component is configured to activate the gas generating cell to generate gas in response to identifying a location of the ingestible device based on the reflectance;
  • the reservoir stores a dispensable substance and a first end of the reservoir is attached to the first end of the housing;
  • a membrane in contact with the gas generating cell and configured to move or deform into the reservoir by a pressure generated by the gas generating cell;
  • a dispensing outlet placed at the first end of the housing, wherein the dispensing outlet is configured to deliver the dispensable substance out of the housing from the reservoir.
  • the pharmaceutical composition is an ingestible device as disclosed in US Patent Application Ser. No. 62/385,553, incorporated by reference herein in its entirety.
  • the pharmaceutical composition is an ingestible device comprising a localization mechanism as disclosed in intemational patent application PCT/US2015/052500, incorporated by reference herein in its entirety.
  • the pharmaceutical composition is not a dart-like dosage form.
  • the stem cell is delivered at a location in the large intestine of the subject. In some embodiments, the location is in the proximal portion of the large intestine. In some embodiments, the location is in the distal portion of the large intestine.
  • the stem cell is delivered at a location in the ascending colon of the subject. In some embodiments, the location is in the proximal portion of the ascending colon. In some embodiments, the location is in the distal portion of the ascending colon.
  • the stem cell is delivered at a location in the cecum of the subject. In some embodiments, the location is in the proximal portion of the cecum. In some embodiments, the location is in the distal portion of the cecum. In some embodiments, the stem cell is delivered at a location in the sigmoid colon of the subject. In some embodiments, the location is in the proximal portion of the sigmoid colon. In some embodiments, the location is in the distal portion of the sigmoid colon. In some embodiments, the stem cell is delivered at a location in the transverse colon of the subject. In some embodiments, the location is in the proximal portion of the transverse colon. In some embodiments, the location is in the distal portion of the transverse colon. In some embodiments, the stem cell is delivered at a location in the descending colon of the subject. In some embodiments, the location is in the proximal portion of the descending colon. In some embodiments, the location is in the distal portion of the descending colon.
  • the stem cell is delivered at a location in the small intestine of the subject. In some embodiments, the location is in the proximal portion of the small intestine. In some embodiments, the location is in the distal portion of the small intestine.
  • the stem cell is delivered at a location in the duodenum of the subject. In some embodiments, the location is in the proximal portion of the duodenum. In some embodiments, the location is in the distal portion of the duodenum.
  • the stem cell is delivered at a location in the jejunum of the subject. In some embodiments, the location is in the proximal portion of the jejunum. In some embodiments, the location is in the distal portion of the jejunum.
  • the stem cell is delivered at a location in the duodenum of the subject and is not delivered at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the duodenum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a site of disease is in the duodenum and no site of disease is present at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the duodenum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a first site of disease is in the duodenum and a second site of disease is in the stomach and no site of disease is present at other locations in the gastrointestinal tract.
  • the stem cell is delivered at a location in the proximal duodenum of the subject and is not delivered at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the proximal duodenum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a site of disease is in the duodenum and no site of disease is present at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the proximal duodenum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a first site of disease is in the duodenum and a second site of disease is in the stomach and no site of disease is present at other locations in the gastrointestinal tract.
  • the stem cell is delivered at a location in the jejunum of the subject and is not delivered at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the jejunum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a site of disease is in the jejunum and no site of disease is present at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the jejunum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a first site of disease is in the jejunum and a second site of disease is in the ileum and no site of disease is present at other locations in the gastrointestinal tract.
  • the stem cell is delivered at a location in the proximal portion of the jejunum of the subject and is not delivered at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the proximal portion of the jejunum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a site of disease is in the j ejunum and no site of disease is present at other locations in the gastrointestinal tract.
  • the stem cell is delivered at a location in the proximal portion of the jejunum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a first site of disease is in the jejunum and a second site of disease is in the ileum and no site of disease is present at other locations in the
  • the stem cell is delivered at a location in the distal portion of the jejunum of the subj ect and is not delivered at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the distal portion of the jejunum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a site of disease is in the jejunum and no site of disease is present at other locations in the gastrointestinal tract.
  • the stem cell is delivered at a location in the distal portion of the jejunum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a first site of disease is in the jejunum and a second site of disease is in the ileum and no site of disease is present at other locations in the
  • the stem cell is delivered at a location in the ileum of the subject. In some embodiments, the location is in the proximal portion of the ileum. In some
  • the location is in the distal portion of the ileum.
  • the stem cell is delivered at a location in the ileum of the subject and is not delivered at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the ileum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a site of disease is in the ileum and no site of disease is present at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the ileum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a first site of disease is in the ileum and a second site of disease is in the cecum and no site of disease is present at other locations in the gastrointestinal tract.
  • the stem cell is delivered at a location in the ileum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a first site of disease is in the ileum and a second site of disease is in the cecum and/or ascending colon, and no site of disease is present at other locations in the gastrointestinal tract.
  • the stem cell is delivered at a location in the proximal portion of the ileum of the subject and is not delivered at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the proximal portion of the ileum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a site of disease is in the ileum and no site of disease is present at other locations in the gastrointestinal tract.
  • the stem cell is delivered at a location in the proximal portion of the ileum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a first site of disease is in the ileum and a second site of disease is in the cecum and no site of disease is present at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the proximal portion of the ileum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a first site of disease is in the ileum and a second site of disease is in the cecum and/or ascending colon, and no site of disease is present at other locations in the
  • the stem cell is delivered at a location in the distal portion of the ileum of the subject and is not delivered at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the distal portion of the ileum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a site of disease is in the ileum and no site of disease is present at other locations in the
  • the stem cell is delivered at a location in the distal portion of the ileum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a first site of disease is in the ileum and a second site of disease is in the cecum and no site of disease is present at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the distal portion of the ileum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a first site of disease is in the ileum and a second site of disease is in the cecum and/or ascending colon, and no site of disease is present at other locations in the gastrointestinal tract.
  • the stem cell is delivered at a location in the cecum of the subject and is not delivered at other locations in the gastrointestinal tract. In some embodiments, the stem cell is delivered at a location in the distal portion of the cecum of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a site of disease is in the cecum and/or ascending colon, and no site of disease is present at other locations in the gastrointestinal tract.
  • the stem cell is delivered at a location in the distal portion of the ileum or the proximal portion of the ascending colon of the subject and is not delivered at other locations in the gastrointestinal tract, wherein a first site of disease is in the cecum and a second site of disease is in the ascending colon, and no site of disease is present at other locations in the gastrointestinal tract.
  • the location at which the stem cell is delivered is proximate to a site of disease.
  • the site of disease may be, for example, an injury, inflamed tissue, or one or more lesions.
  • the location at which the stem cell is delivered is proximate to one or more sites of disease.
  • the stem cell is delivered 50 cm or less from the one or more sites of disease. In some embodiments, the stem cell is delivered 40 cm or less from the one or more sites of disease. In some embodiments, the stem cell is delivered 30 cm or less from the one or more sites of disease. In some embodiments, the stem cell is delivered 20 cm or less from the one or more sites of disease. In some embodiments, the stem cell is delivered 10 cm or less from the one or more sites of disease. In some embodiments, the stem cell is delivered 5 cm or less from the one or more sites of disease. In some embodiments, the stem cell is delivered 2 cm or less from the one or more sites of disease. In some embodiments, the method further comprises identifying the one or more sites of disease by a method comprising imaging of the gastrointestinal tract.
  • imaging of the gastrointestinal tract comprises video imaging. In some embodiments, imaging of the gastrointestinal tract comprises thermal imaging. In some embodiments, imaging of the gastrointestinal tract comprises ultrasound imaging. In some embodiments, imaging of the gastrointestinal tract comprises Doppler imaging. In some embodiments the method does not comprise releasing more than 20 % of the stem cell at a location that is not proximate to a site of disease. In some embodiments the method does not comprise releasing more than 10 % of the stem cell at a location that is not proximate to a site of disease. In some embodiments the method does not comprise releasing more than 5 % of the stem cell at a location that is not proximate to a site of disease.
  • the method does not comprise releasing more than 4 % of the stem cell at a location that is not proximate to a site of disease. In some embodiments the method does not comprise releasing more than 3 % of the stem cell at a location that is not proximate to a site of disease. In some embodiments the method does not comprise releasing more than 2 % of the stem cell at a location that is not proximate to a site of disease.
  • the method comprises releasing the stem cell at a location that is proximate to a site of disease, wherein the stem cell and, if applicable, any carriers, excipients or stabilizers admixed with the stem cell, are substantially unchanged, at the time of release of the stem cell at the location, relatively to the time of administration of the composition to the subject.
  • the method comprises releasing the stem cell at a location that is proximate to a site of disease, wherein the stem cell and, if applicable, any carriers, excipients or stabilizers admixed with the stem cell, are substantially unchanged by any physiological process (such as, but not limited to, degradation in the stomach), at the time of release of the stem cell at the location, relatively to the time of administration of the composition to the subject.
  • any physiological process such as, but not limited to, degradation in the stomach
  • the stem cell is delivered to the location by mucosal contact.
  • the stem cell is delivered to the location by a process that does not comprise systemic transport of the stem cell.
  • the amount of the stem cells that is administered is about 20 million cells to about 500 million cells. In some embodiments, the amount of the stem cells that is administered is about 100 million cells to about 400 million cells. In some embodiments, the amount of the stem cells that is administered is about 120 million cells to about 300 million cells. In some embodiments, the amount of the stem cells that is administered is about 200 million cells. In some embodiments, the amount of the stem cells that is administered is from about 1 mg to about 500 mg. In some embodiments, the amount of the stem cells that is administered is from about 1 mg to about 100 mg. In some embodiments, the amount of the stem cells that is administered is from about 5 mg to about 40 mg.
  • the amount of the stem cell that is administered is less than an amount that is effective when the stem cell is delivered systemically.
  • the amount of the stem cell that is administered is an induction dose.
  • such induction dose is effective to induce remission of the TNF and cytokine storm and healing of acute inflammation and lesions.
  • the induction dose is administered once a day.
  • the induction dose is administered once every three days.
  • the induction dose is administered once a week.
  • the induction dose is administered once a day, once every three days, or once a week, over a period of about 6-8 weeks.
  • the method comprises administering (i) an amount of the stem cell that is an induction dose, and (ii) an amount of the stem cell that is a maintenance dose, in this order. In some embodiments, step (ii) is repeated one or more times. In some embodiments, the induction dose is equal to the maintenance dose. In some embodiments, the induction dose is greater than the maintenance dose. In some embodiments, the induction dose is five times greater than the maintenance dose. In some embodiments, the induction dose is two times greater than the maintenance dose.
  • an induction dose of stem cell and a maintenance dose of stem cell are each administered to the subject by administering a pharmaceutical composition comprising a therapeutically effective amount of the stem cell, wherein the pharmaceutical composition is a device.
  • an induction dose of stem cell is administered to the subject in a different manner from the maintenance dose.
  • the induction dose may be administered systemically.
  • the induction dose may be administered other than orally.
  • the induction dose may be administered rectally.
  • the induction dose may be administered intravenously.
  • the induction dose may be administered subcutaneously.
  • the induction dose may be administered by spray catheter.
  • the concentration of the stem cell delivered at the location in the gastrointestinal tract is 10%, 25%, 50%, 75%, 100%, 200%, 300%, 400%, 500%, 1000%, 2000% greater than the concentration of stem cell in plasma.
  • the method provides a concentration of the stem cell at a location that is a site of disease or proximate to a site of disease that is 2-100 times greater than at a location that is not a site of disease or proximate to a site of disease.
  • the method comprises delivering the stem cell at the location in the gastrointestinal tract as a single bolus.
  • the method comprises delivering the stem cell at the location in the gastrointestinal tract as more than one bolus.
  • the method comprises delivering the stem cell at the location in the gastrointestinal tract in a continuous manner. In some embodiments, the method comprises delivering the stem cell at the location in the gastrointestinal tract over a time period of 20 or more minutes. In some embodiments, the method provides a concentration of the stem cells in the plasma of the subject that is less than 10 ⁇ g/ml. In some embodiments, the method provides a concentration of the stem cells in the plasma of the subject that is less than 3 ⁇ g/ml. In some embodiments, the method provides a concentration of the stem cells in the plasma of the subject that is less than 1 ⁇ g/ml. In some embodiments, the method provides a concentration of the stem cells in the plasma of the subject that is less than 0.3 ⁇ g/ml. In some
  • the method provides a concentration of the stem cells in the plasma of the subject that is less than 0.1 ⁇ g/ml. In some embodiments, the method provides a
  • concentration of the stem cells in the plasma of the subject that is less than 0.01 ⁇ g/ml.
  • the values of the concentration of the stem cells in the plasma of the subject provided herein refer to Ctrough, that is, the lowest value of the concentration prior to administration of the next dose.
  • the concentration of the stem cells in the plasma of the subject may also be measured in CFU (colony -forming units). Accordingly, in some embodiments, the concentration of the stem cells in the plasma of the subject is a value in CFU that is equivalent to the values in ⁇ g/ml disclosed herein.
  • the method does not comprise delivering a stem cell rectally to the subject.
  • the method does not comprise delivering a stem cell via an enema to the subject.
  • the method does not comprise delivering a stem cell via suppository to the subject. In some embodiments, the method does not comprise delivering a stem cell via instillation to the rectum of a subject. In some embodiments, the methods disclosed herein comprise producing a therapeutically effective degradation product of the stem cell in the gastrointestinal tract. In some embodiments, the degradation product is a therapeutic antibody fragment. In some embodiments, a therapeutically effective amount of the degradation product is produced.
  • the methods comprising administering the stem cell in the manner disclosed herein disclosed herein result in a reduced immunosuppressive properties relative to methods of administration of the stem cell systemically. In some embodiments, the methods comprising administering the stem cell in the manner disclosed herein disclosed herein result in reduced immunogenicity relative to methods of administration of the stem cell systemically.
  • the methods provided herein comprise monitoring the progress of the disease. In some embodiments, monitoring the progress of the disease comprises measuring the levels of IBD serological markers. In some embodiments, monitoring the progress of the disease comprises determining mucosal healing at the location of release. In some embodiments, monitoring the progress of the disease comprises determining the Crohn's
  • monitoring the progress of the disease comprises determining the Harvey-Bradshaw Index (HBI) following administration of the stem cell.
  • HBI Harvey-Bradshaw Index
  • Possible markers may include the following: anti-glycan antibodies: anti-Saccharomices cerevisiae (ASCA); anti-laminaribioside (ALCA); anti- chitobioside (ACCA); anti-mannobioside (AMCA); anti-laminarin (anti-L); anti-chitin (anti- C) antibodies: anti-outer membrane porin C (anti-OmpC), anti-Cbirl flagellin; anti-12 antibody; autoantibodies targeting the exocrine pancreas (PAB); perinuclear anti-neutrophil antibody (pANCA).
  • ASCA anti-Saccharomices cerevisiae
  • ACA anti-laminaribioside
  • ACCA anti-chitobioside
  • AMCA anti-mannobioside
  • anti-L anti-laminarin
  • anti- C antibodies: anti-outer membrane porin C (anti-OmpC), anti-Cbirl flagellin; anti-12 antibody; autoantibodies targeting the exocrine pan
  • monitoring the progress of the disease comprises measuring stem cell levels in serum over a period of about 1-14 weeks, such as about 6-8 weeks following administration of the stem cell, including at the 6-8 week time point. In some embodiments, monitoring the progress of the disease comprises measuring stem cell levels in serum over a period of about 52 weeks following administration of the stem cell, including at the 52 week time point.
  • the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises one or more of the following:
  • identifying a subject having a disease of the gastrointestinal tract for example by endoscopy or colonoscopy;
  • evaluating the subject for suitability to treatment for example by determining the patency of the subject's GI tract, for example if the indication is small intestinal diseases, pancolitis, Crohn's disease, or if the patients has strictures or fistulae;
  • CDAI Crohn's Disease Activity Index
  • HBI Harvey-Bradshaw Index
  • an induction dose is a dose of drug that may be administered, for example, at the beginning of a course of treatment, and that is higher than the maintenance dose administered during treatment. An induction dose may also be administered during treatment, for example if the condition of the patients becomes worse.
  • a maintenance dose is a dose of drug that is provided on a repetitive basis, for example at regular dosing intervals.
  • the stem cell is released from an ingestible device.
  • the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises a) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises b) hereinabove.
  • the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises c) hereinabove.
  • the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises d) hereinabove.
  • the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises e) hereinabove.
  • the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises f) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises g) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises a) and b) hereinabove.
  • the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises a) and c) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises a) and d) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises a) and e) hereinabove.
  • the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises a) and f) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises a) and g) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises b) and c) hereinabove.
  • the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises b) and d) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises b) and e) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises b) and f) hereinabove.
  • the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises b) and g) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises c) and d) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises c) and e) hereinabove.
  • the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises c) and f) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises c) and g) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises d) and e) hereinabove.
  • the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises d) and f) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises d) and g) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises e) and f) hereinabove. In some embodiments herein, the method of treating a disease of the gastrointestinal tract that comprises releasing a stem cell at a location in the gastrointestinal tract that is proximate to one or more sites of disease comprises g) hereinabove.
  • one or more steps a) to e) herein comprise endoscopy of the gastrointestinal tract. In some embodiments, one or more steps a) to e) herein comprise colonoscopy of the gastrointestinal tract. In some embodiments, one or more steps a) to e) herein is performed one or more times. In some embodiments, such one or more of such one or more steps a) to e) is performed after releasing the stem cell at the location in the gastrointestinal tract that is proximate to one or more sites of disease.
  • the method comprises administering one or more maintenance doses following administration of the induction dose in step e).
  • an induction dose of stem cell and a maintenance dose of stem cell are each administered to the subject by administering a pharmaceutical composition comprising a therapeutically effective amount of the stem cell.
  • an induction dose of stem cell is administered to the subject in a different manner from the maintenance dose.
  • the maintenance dose may be administered systemically, while the maintenance dose is administered locally using a device.
  • a maintenance dose is administered systemically, and an induction dose is administered using a device every 1, 2, 3, 4, 5, 6, 7, 10, 15, 20, 25, 30, 35, 40, or 45 days.
  • a maintenance dose is administered systemically, and an induction dose is administered when a disease flare up is detected or suspected.
  • the induction dose is a dose of the stem cell administered in an ingestible device as disclosed herein.
  • the maintenance dose is a dose of the stem cell administered in an ingestible device as disclosed herein.
  • the induction dose is a dose of the stem cell administered in an ingestible device as disclosed herein.
  • the maintenance dose is a dose of the stem cell delivered systemically, such as orally with a tablet or capsule, or
  • the induction dose is a dose of the stem cell delivered systemically, such as orally with a tablet or capsule, or subcutaneously, or intravenously.
  • the maintenance dose is a dose of the stem cell administered in an ingestible device as disclosed herein.
  • the induction dose is a dose of the stem cell administered in an ingestible device as disclosed herein.
  • the maintenance dose is a dose of a second agent as disclosed herein delivered systemically, such as orally with a tablet or capsule, or subcutaneously, or intravenously.
  • the induction dose is a dose of a second agent as disclosed herein delivered systemically, such as orally with a tablet or capsule, or subcutaneously, or intravenously.
  • the maintenance dose is a dose of the stem cell administered in an ingestible device as disclosed herein.
  • the patient is not previously treated with a stem cell.
  • the gastrointestinal inflammatory disorder is an
  • the inflammatory bowel disease is ulcerative colitis or Crohn's disease. In one embodiment, the inflammatory bowel disease is ulcerative colitis and the response is selected from clinical response, mucosal healing and remission. In certain embodiments, remission in the patient is determined to be induced when the Mayo Clinic Score ⁇ 2 and no individual subscore >1, which is also referred to as clinical remission. In certain embodiments, mucosal healing is determined to have occurred when the patient is determined to have an endoscopy subscore of 0 or 1 as assessed by flexible sigmoidoscopy. In certain such embodiments, patients who experience mucosal healing are determined to have an endoscopy subscore of 0. In certain embodiments, clinical response is determined to have occurred when the patient experiences a 3 -point decrease and 30% reduction from baseline in MCS and > 1 -point decrease in rectal bleeding subscore or absolute rectal bleeding score of 0 or 1.
  • the method comprises identifying the disease site substantially at the same time as releasing the stem cell.
  • the method comprises monitoring the progress of the disease.
  • monitoring the progress of the disease comprises measuring the weight of the subject over a period of about 1-14 weeks, such as about 6-8 weeks following administration of the stem cell, including at the 6-8 week time point, or over a period of about 52 weeks following administration of the stem cell, including at the 52 week time point.
  • monitoring the progress of the disease comprises measuring the food intake of the subject; measuring the level of blood in the feces of the subject; measuring the level of abdominal pain of the subject; and/or a combination of the above, for example over a period of about 1 -14 weeks, such as about 6-8 weeks following administration of the stem cell, including at the 6-8 week time point, or over a period of about 52 weeks following administration of the stem cell, including at the 52 week time point.
  • the method comprises administering a stem cell with a spray catheter.
  • administering a stem cell with a spray catheter may be performed in step (e) hereinabove.
  • the method does not comprise administering a stem cell with a spray catheter.
  • a "formulation" of a stem cell may refer to either the stem cell in pure form - such as, for example, the lyophilized stem cell - or a mixture of the stem cell with one or more physiologically acceptable carriers, excipients or stabilizers.
  • therapeutic formulations or medicaments can be prepared by mixing the stem cell having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
  • Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride;
  • hexamethonium chloride benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol;
  • Exemplary pharmaceutically acceptable carriers herein further include insterstitial drug dispersion agents such as soluble neutral- active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX ⁇ ®>, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968.
  • sHASEGP soluble neutral- active hyaluronidase glycoproteins
  • rHuPH20 HYLENEX ⁇ ®>, Baxter International, Inc.
  • a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
  • additional glycosaminoglycanases such as chondroitinases.
  • Exemplary lyophilized formulations are described in US Patent No. 6,267,958.
  • Aqueous formulations include those described in US Patent No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.
  • a formulation of a stem cell as disclosed herein, e.g., sustained-release formulations, can further include a mucoadhesive agent, e.g., one or more of polyvinyl pyrolidine, methyl cellulose, sodium carboxyl methyl cellulose, hydroxyl propyl cellulose, carbopol, a polyacrylate, chitosan, a eudragit analogue, a polymer, and a thiomer.
  • mucoadhesive agents that can be included in a formulation with a stem cell are described in, e.g., Peppas et al, Biomaterials 17(16): 1553-1561, 1996; Kharenko et al, Pharmaceutical Chemistry J. 43(4):200-208, 2009; Salamat-Miller et al, Adv. Drug Deliv. Reviews
  • components of a formulation may include any one of the following components, or any combination thereof:
  • the method comprises administering to the subject a pharmaceutical composition that is a formulation as disclosed herein.
  • the formulation is a dosage form, which may be, as an example, a solid form such as, for example, a capsule, a tablet, a sachet, or a lozenge; or which may be, as an example, a liquid form such as, for example, a solution, a suspension, an emulsion, or a syrup.
  • the formulation is not comprised in an ingestible device. In some embodiments wherein the formulation is not comprised in an ingestible device, the formulation may be suitable for oral administration. The formulation may be, for example, a solid dosage form or a liquid dosage form as disclosed herein. In some embodiments wherein the formulation is not comprised in an ingestible device, the formulation may be suitable for rectal administration. The formulation may be, for example, a dosage form such as a suppository or an enema. In embodiments where the formulation is not comprised in an ingestible device, the formulation releases the stem cell at a location in the gastrointestinal tract of the subject that is proximate to one or more sites of disease.
  • Such localized release may be achieved, for example, with a formulation comprising an enteric coating.
  • Such localized release may be achieved, an another example, with a formulation comprising a core comprising one or more polymers suitable for controlled release of an active substance.
  • a non-limiting list of such polymers includes: poly(2-(diethylamino)ethyl methacrylate, 2-
  • the formulation is comprised in an ingestible device as disclosed herein.
  • the formulation may be suitable for oral administration.
  • the formulation may be, for example, a solid dosage form or a liquid dosage form as disclosed herein.
  • the formulation is suitable for introduction and optionally for storage in the device.
  • the formulation is suitable for introduction and optionally for storage in the reservoir comprised in the device. In some embodiments the formulation is suitable for introduction and optionally for storage in the reservoir comprised in the device.
  • a reservoir comprising a therapeutically effective amount of a stem cell wherein the reservoir is configured to fit into an ingestible device.
  • the reservoir comprising a therapeutically effective amount of a stem cell is attachable to an ingestible device.
  • the reservoir comprising a therapeutically effective amount of a stem cell is capable of anchoring itself to the subject's tissue.
  • the reservoir capable of anchoring itself to the subject's tissue comprises silicone.
  • the reservoir capable of anchoring itself to the subject's tissue comprises polyvinyl chloride.
  • the formulation is suitable for introduction in the spray catheters disclosed herein.
  • the formulation/medicament herein may also contain more than one active compound as necessary for the particular indication being treated, for example, those with complementary activities that do not adversely affect each other.
  • the formulation may further comprise another stem cell or a chemotherapeutic agent.
  • Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
  • the active ingredients may also be entrapped in microcapsule prepared, for example, by coacervation techniques or by interfacial polymerization, for
  • hydroxymethylcellulose or gelatin-microcapsule and poly-(methylmethacylate) microcapsule respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in
  • sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the stem cell, which matrices are in the form of shaped articles, e.g., films, or microcapsule.
  • sustained-release matrices include polyesters, hydrogels (for example, poly(2- hydroxy ethyl-methacrylate), or poly(vinylalcohol)), polylactides (U. S. Pat. No.
  • copolymers of L-glutamic acid and ⁇ ethyl-L-glutamate copolymers of L-glutamic acid and ⁇ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-gly colic acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid-gly colic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-gly colic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
  • encapsulated stem cells When encapsulated stem cells remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
  • Pharmaceutical formulations may contain one or more stem cells. The pharmaceutical formulations may be formulated in any manner known in the art.
  • the formulations include one or more of the following components: a sterile diluent (e.g., sterile water or saline), a fixed oil, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents, antibacterial or antifungal agents, such as benzyl alcohol or methyl parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like, antioxidants, such as ascorbic acid or sodium bisulfite, chelating agents, such as ethylenediaminetetraacetic acid, buffers, such as acetates, citrates, or phosphates, and isotonic agents, such as sugars (e.g., dextrose), polyalcohols (e.g., mannitol or sorbitol), or salts (e.g., sodium chloride), or any combination thereof.
  • a sterile diluent e.g., sterile water
  • Liposomal suspensions can also be used as pharmaceutically acceptable carriers (see, e.g., U. S. Patent No. 4,522,811, incorporated by reference herein in its entirety).
  • the formulations can be formulated and enclosed in ampules, disposable syringes, or multiple dose vials. Where required, proper fluidity can be maintained by, for example, the use of a coating, such as lecithin, or a surfactant.
  • Controlled release of the stem cell can be achieved by implants and microencapsulated delivery systems, which can include biodegradable, biocompatible polymers (e.g., ethylene vinyl acetate, polyanhydrides, poly gly colic acid, collagen, polyorthoesters, and polylactic acid; Alza Corporation and Nova Pharmaceutical, Inc.).
  • biodegradable, biocompatible polymers e.g., ethylene vinyl acetate, polyanhydrides, poly gly colic acid, collagen, polyorthoesters, and polylactic acid; Alza Corporation and Nova Pharmaceutical, Inc.
  • the stem cell is present in a pharmaceutical formulation within the device.
  • the stem cell is present in solution within the device.
  • the stem cell is present in a suspension in a liquid medium within the device.
  • data obtained from cell culture assays and animal studies can be used in formulating an appropriate dosage of any given stem cell.
  • the effectiveness and dosing of any stem cell can be determined by a health care professional or veterinary professional using methods known in the art, as well as by the observation of one or more disease symptoms in a subject (e.g., a human). Certain factors may influence the dosage and timing required to effectively treat a subject (e.g., the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and the presence of other diseases).
  • the subject is further administered an additional therapeutic agent (e.g., any of the additional therapeutic agents described herein).
  • the additional therapeutic agent can be administered to the subject at substantially the same time as the stem cell or pharmaceutical composition comprising it is administered and/or at one or more other time points.
  • the additional therapeutic agent is formulated together with the stem cell (e.g., using any of the examples of formulations described herein).
  • the subject is administered a dose of the stem cell at least once a month (e.g., at least twice a month, at least three times a month, at least four times a month, at least once a week, at least twice a week, three times a week, once a day, or twice a day).
  • the stem cell may be administered to a subject chronically.
  • Chronic treatments include any form of repeated administration for an extended period of time, such as repeated administrations for one or more months, between a month and a year, one or more years, more than five years, more than 10 years, more than 15 years, more than 20 years, more than 25 years, more than 30 years, more than 35 years, more than 40 years, more than 45 years, or longer.
  • Chronic treatments can involve regular administrations, for example one or more times a day, one or more times a week, or one or more times a month.
  • chronic treatment can include administration (e.g., intravenous administration) about every two weeks (e.g., between about every 10 to 18 days).
  • a suitable dose may be the amount that is the lowest dose effective to produce a desired therapeutic effect. Such an effective dose will generally depend upon the factors described herein.
  • an effective daily dose of stem cell can be administered as two, three, four, five, or six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
  • the stem cells disclosed herein may be optionally be used with additional agents in the treatment of the diseases disclosed herein.
  • agents for treating or preventing inflammatory bowel disease in such adjunct therapy include substances that suppress cytokine production, down-regulate or suppress self-antigen expression, or mask the MHC antigens.
  • agents include 2- amino-6-aryl-5 -substituted pyrimidines (see U.S. Patent No.
  • nonsteroidal antiinflammatory drugs NSAIDs
  • ganciclovir tacrolimus
  • lucocorticoids such as Cortisol or aldosterone
  • anti-inflammatory agents such as a cyclooxygenase inhibitor; a 5 - lipoxygenase inhibitor; or a leukotriene receptor antagonist
  • purine antagonists such as azathioprine or mycophenolate mofetil (MMF)
  • alkylating agents such as cyclophosphamide; bromocryptine; danazol; dapsone; glutaraldehyde (which masks the MHC antigens, as described in U.S. Patent No.
  • anti-idiotypic antibodies for MHC antigens and MHC fragments include cyclosporine; 6-mercaptopurine; steroids such as corticosteroids or glucocorticosteroids or glucocorticoid analogs, e.g., prednisone, methylprednisolone, including SOLU-MEDROL®, methylprednisolone sodium succinate, and dexamethasone; dihydrofolate reductase inhibitors such as methotrexate (oral or subcutaneous); anti-malarial agents such as chloroquine and hydroxychloroquine; sulfasalazine; leflunomide; cytokine or cytokine receptor antibodies or antagonists including anti-interferon-alpha, -beta, or -gamma antibodies, anti-tumor necrosis factor(TNF)-alpha antibodies (infliximab (REMICADE®) or adalimumab
  • steroids such as
  • TGF-beta transforming growth factor-beta
  • streptodomase RNA or DNA from the host
  • FK506 transforming growth factor-beta
  • RS-61443 chlorambucil
  • deoxyspergualin rapamycin
  • T-cell receptor Cohen et al, U.S. Patent No.
  • T-cell receptor fragments Offner et al, Science, 251 : 430-432 (1991); WO 90/11294; Ianeway, Nature, 341 : 482 (1989); and WO 91/01133
  • BAFF antagonists such as BAFF or BR3 antibodies or immunoadhesins and zTNF4 antagonists (for review, see Mackay and Mackay, Trends Immunol, 23: 113-5 (2002) and see also definition below); biologic agents that interfere with T cell helper signals, such as anti-CD40 receptor or anti- CD40 ligand (CD 154), including blocking antibodies to CD40-CD40 ligand.
  • CD40-CD40 ligand CD 154
  • adjunct agents also include the following: budenoside; epidermal growth factor; aminosalicylates; metronidazole;
  • agents for UC are sulfasalazine and related salicylate-containing drugs for mild cases and corticosteroid drugs in severe cases.
  • Topical administration of either salicylates or corticosteroids is sometimes effective, particularly when the disease is limited to the distal bowel, and is associated with decreased side effects compared with systemic use.
  • Supportive measures such as administration of iron and antidiarrheal agents are sometimes indicated.
  • Azathioprine, 6-mercaptopurine and methotrexate are sometimes also prescribed for use in refractory corticosteroid-dependent cases.
  • a stem cell as described herein can be administered with one or more of: a CHST15 inhibitor, a IL-6 receptor inhibitor, an IL-12/IL-23 inhibitor, an integrin inhibitor, a JAK inhibitor, a SMAD7 inhibitor, a IL-13 inhibitor, an IL-1 receptor inhibitor, a TLR agonist, an immunosuppressant, or a TNF inhibitor.
  • a stem cell as described herein can be administered with a vitamin C infusion, one or more
  • corticosteroids and optionally thiamine.
  • the methods disclosed herein comprise administering (i) the stem cell as disclosed herein, and (ii) a second agent orally, intravenously or subcutaneously, wherein the second agent in (ii) is the same stem cell in (i); a different stem cell; or an agent having a different biological target from the stem cell.
  • the methods disclosed herein comprise administering (i) the stem cell in the manner disclosed herein, and (ii) a second agent orally, intravenously or
  • the second agent in (ii) is an agent suitable for treating an inflammatory bowel disease.
  • the stem cell is administered prior to the second agent. In some embodiments, the stem cell is administered after the second agent. In some embodiments, the stem cell and the second agent are administered substantially at the same time. In some embodiments, the stem cell is delivered prior to the second agent. In some embodiments, the stem cell is delivered after the second agent. In some embodiments, the stem cell and the second agent are delivered substantially at the same time.
  • the second agent is an agent suitable for the treatment of a disease of the gastrointestinal tract. In some embodiments, the second agent is an agent suitable for the treatment of an inflammatory bowel disease. In some embodiments, the second agent is administered intravenously. In some embodiments, the second agent is administered subcutaneously. In some embodiments, the second agent is methotrexate. In some embodiments, delivery of the stem cell to the location, such as delivery to the location by mucosal contact, results in systemic immunogenicity levels at or below systemic immunogenicity levels resulting from administration of the stem cell systemically.
  • the method comprises administering the stem cell in the manner disclosed herein and a second agent, wherein the amount of the second agent is less than the amount of the second agent when the stem cell and the second agent are both administered systemically.
  • the second agent is a stem cell.
  • the method comprises administering the stem cell in the manner disclosed herein and does not comprise administering a second agent.
  • Colitis is experimentally induced to in mice via the dextran sulfate sodium (DSS)- induced colitis model. This model is widely used because of its simplicity and many similarities with human ulcerative colitis. Briefly, mice are subjected to DSS via cecal catheterization, which is thought to be directly toxic to colonic epithelial cells of the basal crypts, for several days until colitis is induced.
  • DSS dextran sulfate sodium
  • mice are allocated to one of seven cohorts, depending on the agent that is administered:
  • Expanded allogeneic adipose-derived mesenchymal stem cells 200 million cells
  • Expanded allogeneic adipose-derived mesenchymal stem cells 400 million cells
  • control or agent is applied to a damaged mucosal surface of the bowel via administration through a cecal catheter at the dose levels described above.
  • the animals are separated into two groups. One group receives a single dose of the control or agent on day 10 or 12. The other group receives daily (or similar) dosing of the control or agent. Analysis
  • TLR levels are determined in blood, feces, and tissue (tissue levels are determined after animal sacrifice).
  • tissue samples levels HER2 are additionally determined, and the level of TLR is normalized to the level of HER2.
  • other cytokine levels are determined in tissue (e.g., phospho STAT 1, STAT 3 and STAT 5), in plasma (e.g., VEGF, VCAM, ICAM, IL-6), or both.
  • Pharmacokinetics are determined both systemically (e.g., in the plasma) and locally (e.g., in colon tissue).
  • blood and/or feces is collected from the animals at one or more timepoints after administration (e.g., plasma samples are collected at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and/or 8 hours after administration).
  • Local/colon tissue samples are collected once after animal sacrifice.
  • TNBS trinitrobenzene sulfonic acid
  • the TNBS is retained at the dose site for 12 minutes by use of two Foley catheters with 60-ml balloons placed in the mid-section of the descending colon below the dose site. A second animal is similarly treated, but with a solution containing 10 grams of TNBS.
  • An Endoscope is employed to positively identify the dose site in both animals prior to TNBS administration. Dosing and endoscopy are performed by a veterinary surgeon seven (7) days after TNBS administration, after light anesthesia, the dose site and mucosal tissues above and below the dose site are evaluated by the veterinary surgeon using an endoscope. Pinch Biopsies are obtained necessary, as determined by the surgeon.
  • the animals may be euthanized for tissue collection on that day, or may proceed on study pending the results of subsequent endoscopy exams for 1 to 4 more days. Macroscopic and microscopic alterations of colonic architecture, possible necrosis, thickening of the colon, and substantial histologic changes are observed at the proper TNBS dose.
  • Clinical signs e.g., ill health, behavioral changes, etc.
  • Clinical signs are recorded at least daily during acclimation and throughout the study. Additional pen-side observations are conducted twice daily (once-daily on weekends). Body weight is measured for both animals Days 1 and 7 (and on the day of euthanasia if after Day 7).
  • the animals are euthanized via injection of a veterinarian-approved euthanasia solution.
  • colon tissues are collected, opened, rinsed with saline, and a detailed macroscopic examination of the colon is performed to identify macroscopic finings related to TNBS-damage. Photos are taken. Tissue samples are taken from the proximal, mid, and distal transverse colon; the dose site; the distal colon; the rectum; and the anal canal. Samples are placed into NBF and evaluated by a board certified veterinary pathologist.
  • TNBS TNBS to induce chronic colitis on Day -6. All animals are fasted prior to colitis induction on Day -7.
  • the TNBS is dissolved in 25% ethanol then instilled into the colon intra-rectally using a flexible plastic ball-tip gavage needle. Approximately seven (7) days after induction, macroscopic and microscopic alterations of colonic architecture are apparent: some necrosis, thickening of the colon, substantial histologic changes that only partially resolve by Day 60.
  • test article On Day 0, the test article is applied to a damaged mucosal surface of the bowel via intrarectal administration or subcutaneous injection by a veterinary surgeon at the dose levels and volume described above.
  • Clinical observations are conducted at least once daily.
  • Clinical signs e.g., ill health, behavioral changes, etc.
  • Clinical signs are recorded on all appropriate animals at least daily prior to the initiation of experiment and throughout the study until termination. Additional clinical observations may be performed if deemed necessary.
  • Animals whose health condition warrants further evaluation are examined by a Clinical Veterinarian. Body weight is measured for all animals Days -6, 0, and after the last blood collections.
  • Blood is collected (cephalic, jugular, and/or catheter) into EDTA tubes during acclimation on Day-7, just prior to dose on Day 0, and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours post-dose.
  • the EDTA samples are split into two aliquots and one is centrifuged for pharmacokinetic plasma and either analyzed immediately, or stored frozen (-80°C) for later pharmacokinetic analyses. The remaining sample of whole blood is used for pharmacodynamic analyses.
  • Feces is collected Day -7, 0 and 0.5, 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose, and either analyzed immediately, or flash-frozen on liquid nitrogen and stored frozen at -70°C pending later analysis of drug levels and inflammatory cytokines.
  • colon tissues are collected, opened, rinsed with saline, and a detailed macroscopic examination of the colon is performed to identify macroscopic finings related to TNBS-damage.
  • Triplicate samples of normal and damaged tissues are either analyzed immediately, or are flash-frozen on liquid nitrogen and stored frozen at -70°C pending later analysis of drug concentration, inflammatory cytokines and histology.
  • Samples are analyzed for drug levels (local mucosal tissue levels and systemic circulation levels), and for levels of TLR. Terminal Procedures
  • Animals are euthanized as per a schedule where one animal each of Vehicle and Treated Control groups is euthanized at 6 and 48 hours post-dose, and one animal of each the drug groups are euthanized at 6, 12, 24 and 48 hours post-dose. Animals are discarded after the last blood collection unless retained for a subsequent study.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La présente invention concerne des procédés et des compositions pour traiter des maladies du tractus gastro-intestinal avec une cellule souche.
PCT/US2017/024997 2017-03-30 2017-03-30 Procédés et dispositifs pouvant être ingérés pour la libération régio-spécifique de cellules souches au site d'une maladie du tractus gastro-intestinal WO2018182612A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2017/024997 WO2018182612A1 (fr) 2017-03-30 2017-03-30 Procédés et dispositifs pouvant être ingérés pour la libération régio-spécifique de cellules souches au site d'une maladie du tractus gastro-intestinal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/024997 WO2018182612A1 (fr) 2017-03-30 2017-03-30 Procédés et dispositifs pouvant être ingérés pour la libération régio-spécifique de cellules souches au site d'une maladie du tractus gastro-intestinal

Publications (1)

Publication Number Publication Date
WO2018182612A1 true WO2018182612A1 (fr) 2018-10-04

Family

ID=63678115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/024997 WO2018182612A1 (fr) 2017-03-30 2017-03-30 Procédés et dispositifs pouvant être ingérés pour la libération régio-spécifique de cellules souches au site d'une maladie du tractus gastro-intestinal

Country Status (1)

Country Link
WO (1) WO2018182612A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021180850A1 (fr) * 2020-03-11 2021-09-16 Mesoblast International Sàrl Procédé de traitement d'une maladie intestinale inflammatoire i
WO2021180851A1 (fr) * 2020-03-11 2021-09-16 Mesoblast International Sàrl Procédé de traitement d'une maladie intestinale inflammatoire ii
US11179341B2 (en) 2017-05-17 2021-11-23 Massachusetts Institute Of Technology Self-righting articles
US11202903B2 (en) 2018-05-17 2021-12-21 Massachusetts Institute Of Technology Systems for electrical stimulation
EP3873538A4 (fr) * 2018-10-30 2022-07-06 Vitabolus Inc. Administration orale de cellules thérapeutiques de mammifère
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components
US11771829B2 (en) 2019-02-01 2023-10-03 Massachusetts Institute Of Technology Systems and methods for liquid injection

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021307A1 (fr) * 1991-05-30 1992-12-10 Schentag Jerome J Procede et capsule de telemesure
US5318557A (en) * 1992-07-13 1994-06-07 Elan Medical Technologies Limited Medication administering device
WO2001045789A2 (fr) * 1999-12-21 2001-06-28 Phaeton Research Ltd Dispositif ingerable
US20030077244A1 (en) * 2000-08-25 2003-04-24 Jens Petersen Polyacrylamide hydrogel for the treatment of incontinence and vesicouretal reflux
WO2006055743A2 (fr) * 2004-11-18 2006-05-26 Franco, Wayne Combinaison de therapie au facteur de croissance et de therapie cellulaire pour le traitement de maladies aigues et chroniques des organes
WO2008053396A2 (fr) * 2006-10-31 2008-05-08 Koninklijke Philips Electronics N.V. Dispositif de dosage ingérable à buses multiples pour administration de médicaments dans le tractus gastro-intestinal
WO2012158648A1 (fr) * 2011-05-13 2012-11-22 Massachusetts Institute Of Technology Procédé et appareil permettant d'administrer une substance
WO2014134539A1 (fr) * 2013-02-28 2014-09-04 President And Fellows Of Harvard College Procédés et compositions pour mobiliser des cellules souches
WO2015194710A1 (fr) * 2014-06-17 2015-12-23 가톨릭대학교 산학협력단 Composition comprenant des cellules souches mésenchymateuses traitées avec un inhibiteur de stat3 en tant que principe actif pour la prévention ou le traitement de maladies immunitaires
WO2016049602A1 (fr) * 2014-09-25 2016-03-31 Progenity, Inc. Dispositif de pilules électromécaniques avec capacités de localisation
US20160213234A1 (en) * 2015-01-26 2016-07-28 The Chinese University Of Hong Kong Endoscopic capsule and endoscopic system
WO2016193964A1 (fr) * 2015-05-31 2016-12-08 Check-Cap Ltd. Capsule d'administration d'un médicament

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021307A1 (fr) * 1991-05-30 1992-12-10 Schentag Jerome J Procede et capsule de telemesure
US5318557A (en) * 1992-07-13 1994-06-07 Elan Medical Technologies Limited Medication administering device
WO2001045789A2 (fr) * 1999-12-21 2001-06-28 Phaeton Research Ltd Dispositif ingerable
US20030077244A1 (en) * 2000-08-25 2003-04-24 Jens Petersen Polyacrylamide hydrogel for the treatment of incontinence and vesicouretal reflux
WO2006055743A2 (fr) * 2004-11-18 2006-05-26 Franco, Wayne Combinaison de therapie au facteur de croissance et de therapie cellulaire pour le traitement de maladies aigues et chroniques des organes
WO2008053396A2 (fr) * 2006-10-31 2008-05-08 Koninklijke Philips Electronics N.V. Dispositif de dosage ingérable à buses multiples pour administration de médicaments dans le tractus gastro-intestinal
WO2012158648A1 (fr) * 2011-05-13 2012-11-22 Massachusetts Institute Of Technology Procédé et appareil permettant d'administrer une substance
WO2014134539A1 (fr) * 2013-02-28 2014-09-04 President And Fellows Of Harvard College Procédés et compositions pour mobiliser des cellules souches
WO2015194710A1 (fr) * 2014-06-17 2015-12-23 가톨릭대학교 산학협력단 Composition comprenant des cellules souches mésenchymateuses traitées avec un inhibiteur de stat3 en tant que principe actif pour la prévention ou le traitement de maladies immunitaires
WO2016049602A1 (fr) * 2014-09-25 2016-03-31 Progenity, Inc. Dispositif de pilules électromécaniques avec capacités de localisation
US20160213234A1 (en) * 2015-01-26 2016-07-28 The Chinese University Of Hong Kong Endoscopic capsule and endoscopic system
WO2016193964A1 (fr) * 2015-05-31 2016-12-08 Check-Cap Ltd. Capsule d'administration d'un médicament

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVE M. ET AL.: "Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis", vol. 21, no. 11, November 2015 (2015-11-01), pages 2696 - 2707 *
HAWKEY C.J. : "Stem Cells as treatment in inflammatory bowel disease", DIG DIS, 3 January 2012 (2012-01-03), pages 134 - 139, DOI: 10.1159/000342740 *
MIYAMOTO, SHUICHI; OHNISHI, SHUNSUKE; ONISHI, REIZO; TSUCHIYA, IKUKI; HOSONO, HIDETAKA; KATSURADA, TAKEHIKO; YAMAHARA, KENICHI; TA: "Therapeutic effects of human amnion-derived mesenchymal stem cell transplantation and conditioned medium enema in rats with trinitrobenzene sulfonic acid-induced colitis", AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, vol. 9, no. 3, 15 March 2017 (2017-03-15), pages 940 - 952 *
PETER J. VAN DER SCHAAR, J. FRITS DIJKSMAN, HENNY BROEKHUIZEN-DE GAST, JEFF SHIMIZU, NIELS VAN LELYVELD, HANS ZOU, VENTZESLAV IORD: "A novel ingestible electronic drug delivery and monitoring device", GASTROINTESTINAL ENDOSCOPY., ELSEVIER, NL, vol. 78, no. 3, 1 September 2013 (2013-09-01), NL, pages 520 - 528, XP055349388, ISSN: 0016-5107, DOI: 10.1016/j.gie.2013.03.170 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
US12036324B2 (en) 2017-05-17 2024-07-16 Massachusetts Institute Of Technology Self-righting systems and related components and methods
US11179341B2 (en) 2017-05-17 2021-11-23 Massachusetts Institute Of Technology Self-righting articles
US11607390B2 (en) 2017-05-17 2023-03-21 Massachusetts Institute Of Technology Self-righting systems and related components and methods
US11207272B2 (en) 2017-05-17 2021-12-28 Massachusetts Institute Of Technology Tissue anchoring articles
US11311489B2 (en) 2017-05-17 2022-04-26 Massachusetts Institute Of Technology Components with high API loading
US11369574B2 (en) 2017-05-17 2022-06-28 Massachusetts Institute Of Technology Self-righting systems and related components and methods
US11541016B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
US12268832B2 (en) 2017-05-17 2025-04-08 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
US12064520B2 (en) 2017-05-17 2024-08-20 Massachusetts Institute Of Technology Components with high API loading
US11712421B2 (en) 2017-05-17 2023-08-01 Massachusetts Institute Of Technology Self-actuating articles
US12059562B2 (en) 2018-05-17 2024-08-13 Massachusetts Institute Of Technology Systems for electrical stimulation
US11202903B2 (en) 2018-05-17 2021-12-21 Massachusetts Institute Of Technology Systems for electrical stimulation
EP3873538A4 (fr) * 2018-10-30 2022-07-06 Vitabolus Inc. Administration orale de cellules thérapeutiques de mammifère
US11707489B2 (en) 2018-10-30 2023-07-25 Ranas, Llc Oral delivery of therapeutic mammalian cells
US11771829B2 (en) 2019-02-01 2023-10-03 Massachusetts Institute Of Technology Systems and methods for liquid injection
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components
WO2021180850A1 (fr) * 2020-03-11 2021-09-16 Mesoblast International Sàrl Procédé de traitement d'une maladie intestinale inflammatoire i
WO2021180851A1 (fr) * 2020-03-11 2021-09-16 Mesoblast International Sàrl Procédé de traitement d'une maladie intestinale inflammatoire ii
CN115361957A (zh) * 2020-03-11 2022-11-18 迈索布拉斯特国际有限公司 治疗炎症性肠病的方法i
CN115297875A (zh) * 2020-03-11 2022-11-04 迈索布拉斯特国际有限公司 治疗炎症性肠病的方法ii

Similar Documents

Publication Publication Date Title
WO2018182612A1 (fr) Procédés et dispositifs pouvant être ingérés pour la libération régio-spécifique de cellules souches au site d'une maladie du tractus gastro-intestinal
EP3601531B1 (fr) Traitement d'une maladie du tractus gastro-intestinal avec des biopharmaceutiques vivants
EP3554485B9 (fr) Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de jak et dispositifs associés
EP3554540B1 (fr) Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur des interleukines il-12/il-23 libéré à l'aide d'un dispositif ingérable
WO2018111326A1 (fr) Procédés et dispositifs ingérables pour la libération régio-spécifique d'immunosuppresseurs au niveau du site d'une maladie du tractus gastro-intestinal
KR102616436B1 (ko) Tnf 저해제로의 위장관 질환의 치료
WO2018182623A1 (fr) Méthodes et dispositifs ingérables pour la libération régiospécifique d'inhibiteurs de chst15 au niveau du site d'une maladie du tractus gastro-intestinal
Gamboa et al. In vitro and in vivo models for the study of oral delivery of nanoparticles
EP3723801B1 (fr) Traitement d'une maladie inflammatoire à l'aide d'un dispositif ingestible de libération d'un modulateur immunitaire
WO2018182641A1 (fr) Méthodes et dispositifs pouvant être ingérés pour la libération régio-spécifique d'inhibiteurs il-13 au site d'une maladie du tractus gastro-intestinal
EP3600416B1 (fr) Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
WO2018183931A1 (fr) Traitement d'une maladie du tractus gastro-intestinal au moyen d'il-10 ou d'un agoniste d'il-10
EP3485879A1 (fr) Formulation pharmaceutique orale comprenant bactéries
WO2018111324A1 (fr) Procédés et dispositifs ingérables pour la libération régio-spécifique d'agonistes de tlr au niveau du site d'une maladie du tractus gastro-intestinal
WO2019036363A1 (fr) Traitement d'une maladie du tractus gastro-intestinal avec le glatiramer ou un sel pharmaceutiquement acceptable de celui-ci
CA2903037C (fr) Formulations pharmaceutiques contenant un glycosaminoglycane
WO2018111327A1 (fr) Méthodes et dispositifs ingérables pour la libération régio-spécifique d'inhibiteurs de jak sur le site d'une maladie du tractus gastro-intestinal
WO2018111323A1 (fr) Méthodes et dispositifs ingérables pour la libération régio-spécifique d'inhibiteurs de smad7 au niveau du site d'une maladie du tractus gastro-intestinal
US9539265B2 (en) Pharmaceutical formulation containing glycosaminoglycan
WO2018111321A1 (fr) Méthodes et dispositifs ingérables pour la libération régio-spécifique d'inhibiteurs d'il-12/il-23 au niveau du site d'une affection touchant le tractus gastro-intestinal
WO2018111325A1 (fr) Méthodes et dispositifs ingérables pour la libération régio-spécifique d'inhibiteurs d'il-6r au niveau du site d'une maladie du tractus gastro-intestinal
WO2018111328A1 (fr) Méthodes et dispositifs ingérables pour la libération régio-spécifique d'inhibiteurs de tnf sur le site d'une maladie du tractus gastro-intestinal
EP4302816A1 (fr) Administration de médicament par voie orale
WO2024007038A2 (fr) Compositions et méthodes pour le traitement d'une inflammation intestinale
Van Denberghe THE PIG AS A MODEL FOR CROHN AND INNOVATIVE TREATMENT STRATEGIES

Legal Events

Date Code Title Description
WD Withdrawal of designations after international publication
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载